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ABSTRACT 
 
Short-bowel syndrome (SBS) is a costly condition primarily affecting very low 
birth weight, premature infants with long-term detriment to nutritional adequacy and 
quality of life. Necrotizing enterocolitis (NEC) -the primary cause of surgical resection 
leading to pediatric SBS- has an ill-defined etiology that is associated with intestinal 
microbial dysbiosis, defined by altered intestinal microbiota, decreased bacterial 
diversity, and antibiotic use.  
SBS is associated with an enteroendocrine cascade beginning with intestinal 
secretion of glucagon-like peptide-2 (GLP-2), an intestinotrophic hormone, stimulating 
innate intestinal adaptation. Treatments such as prebiotics and probiotics that increase 
luminal production of short-chain fatty acids (SCFA), especially butyrate, could further 
enhance this process through stimulating higher secretion of GLP-2 from enteroendocrine 
L-cells. Hence, manipulation of the intestinal microbiota is a logical target for the 
treatment of NEC and SBS, given its ability to produce butyrate and other SCFA through 
microbial syntrophy. 
In this series of studies, we: 
1) Identified key existing information related to the etiology, treatment, and physiology 
related to SBS and the intestinal microbiota (literature review) 
2) Investigated potential interactions between abundances of ileal and colonic butyrate 
and lactate-producing bacterial populations and their modulation of intestinal nutrient 
transport 
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3) Determined the associations between changes in the intestinal microbiota, intestinal 
epithelium, and enteroendocrine system related to intestinal adaptation in the distal ileum 
and proximal colon  
4) Identified key traits that differentiated our four treatment groups utilizing linear 
discriminant analysis, and developed statistical models that could identify which 
variables accounted for changes in specific structural and functional adaptations using 
multiple linear regression. 
 Studies 2-4 were conducted within the same group of piglets receiving an 80% 
ileojejunal resection, receiving 80% of their nutritional needs via parenteral nutrition and 
20% of their needs via enteral nutrition, supplemented with: [1] nothing, control (CON); 
[2] 10g/L short-chain fructooligosaccharide (scFOS), prebiotic (PRE); [3] 109 colony 
forming units Lactobacillus rhamnosus GG (LGG), probiotic (PRO); OR [4] scFOS + 
LGG.  
Treatments with scFOS were associated with increased chao1 alpha diversity (P = 
0.0427) and increased butyrate-producing bacteria in the ileal digesta (P = 0.04) (as 
measured by 16s, V3-V5 DNA sequencing), which was associated with increased 
electrogenic glucose absorption as measured ex vivo in modified Ussing chambers (R2 = 
0.477, P = 0.0529). The probiotic, LGG, primarily colonized the ileal digesta where it 
increased total Lactobacillus (all P = 0.04). Specifically, PRO increased D-lactate 
producing Lactobacillus (P = 0.0712) with negative effects on ileal peptide absorption 
(R2 = -0.485, P = 0.0567). L-cell density, as assessed by immunofluorescence, did not 
differ between treatments in the ileum (P = 0.602) or the colon (P = 0.4319), but L-cell 
density was higher in the ileum vs the colon (P = 0.0003). mRNA expression of primary 
	 iv 
GLP-2 signaling elements was enhanced by PRE in the ileum. Most notably, PRE 
decreased expression of Dipeptidyl-peptidase 4 (P = 0.0027). mRNA expression of 
secondary GLP-2 signaling elements was diminished by PRO in the colon. Treatments 
with scFOS (PRE and SYN) decreased abundance of bacterial species detrimental to 
GLP-2 signaling, including Enterococcus faecalis (P = 0.04) and Escherichia coli 
E851/71 (P = 0.01).  
Three linear models were generated to predict ileal villus height (R2 adjusted = 
0.890, 0.793, and 0.753; all P < 0.001) two linear models were generated to predict 
colonic electrogenic glutamine transport (R2 adjusted = 0.815 and 0.655; both P < 0.001), 
and one LDA was conducted to differentiate between treatment groups for each the ileum 
and the colon (all groups completely differentiated with 100% confidence and P < 
0.0001).  
Overall, this data demonstrates that overabundance of Lactobacillus, especially 
those that produce D-lactate, contraindicates the use of LGG with scFOS as a synbiotic 
combination. The increase in total butyrate-producers and glucose absorption associated 
with scFOS reinforces its potential usefulness in the treatment of SBS. Furthermore, the 
associated increase in butyrate may enhance primary GLP-2 signaling through altered 
gene expression and decreasing abundance of detrimental bacterial species, highly 
contributing to predictions of enhanced structural and functional adaptation in the ileum 
and colon. 
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CHAPTER 1: LITERATURE REVIEW 	
1.1 SHORT-BOWEL SYNDROME IN INFANTS 
1.1.1 Characterization, Morbidity, Mortality, and Cost 
Short-bowel syndrome (SBS) is a costly condition primarily affecting very low birth 
weight, premature infants with long-term detriment to quality of life. The most common 
gastrointestinal emergency and cause of SBS in infants is necrotizing enterocolitis (NEC) (Neu 
& Walker, 2011).  Incidence of NEC is estimated at 0.003-0.24% of all live births in the United 
States but in the highest risk population (premature, very low birth weight infants), incidence is 
around 10% (Christensen, Gordon, & Besner, 2010; Dominguez & Moss, 2012; Guthrie et al., 
2003). Standard treatment of NEC involves surgical resection of the affected tissue and is 
required in up to 50% of NEC cases. Removal of the necrotic tissue often results in a dramatic 
reduction of intestinal mass and altered continuity, inducing SBS - a form of intestinal failure 
(IF). 
IF is defined by a reduction in functional gastrointestinal tissue below the minimum 
amount needed to facilitate adequate digestion and absorption to sustain life, with respect to 
macronutrients, fluid, and electrolytes (O'Keefe et al., 2006; Youssef et al., 2012). Pediatric IF is 
further complicated by the demands of growth and development. This results in dependence on 
parenteral nutrition (PN), which prevents death from malnutrition and dehydration, but should 
not be considered an ultimate solution due to serious, long-term consequences including 
catheter-related sepsis and PN-associated fatty liver disease (Le et al., 2010).  
SBS is accompanied by other long-term, debilitating comorbidities such as: chronic 
diarrhea, various metabolic dysfunctions, different levels of PN dependency, and depression into 
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adulthood (Kelly, Tappenden, & Winkler, 2014). Mortality following surgical resection occurs in 
20-50% of patients, which is higher in infants with lower birth weights and gestational ages. 
Those who do survive can expect medical costs of at least $260,000 and a length of stay 60 days 
longer than other premature infants (Christensen et al., 2010; Gephart et al., 2012). Treating 
intestinal failure accounts for 20% of the total cost incurred by NICUs in the United States 
annually (Gephart et al., 2012); Therefore, development of treatments to reduce risk, morbidity, 
and mortality due to SBS could save thousands of lives and millions of dollars annually. 
 
1.1.2 Intestinal Adaptation 
As a natural and enhanceable response to resection, intestinal adaptation can mitigate 
morbidity and mortality. This process encompasses both structural adaptations including: 
hyperplasia, angiogenesis, and bowel dilation and elongation as well as functional adaptations 
including: increased abundance of nutrient transporters and cells, acceleration of crypt cell 
differentiation, and reduced transit rate of the digesta (Tappenden, 2014).  Together, these 
changes facilitate higher nutrient processing and absorption. 
Age and preservation of specific intestinal segments influence an individual’s potential 
for intestinal adaptation. Infants, who are still developing, possess a higher aptitude than adults. 
Retained ileal tissue displays a higher propensity for adaptive physiological changes such as 
increased segment length, villus restructuring (changes in height and width), and nutrient 
processing capacity than other segments. Preservation of the ileocecal valve allows for better 
regulation of transit rate, thus optimizing time of contact of nutrients with digestive enzymes and 
the absorptive epithelial surface area. In all individuals, stimulation of intestinal adaptation is 
vital, as prognosis and future PN dependency are ultimately dependent on the length and 
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functional capacity of the remaining intestine (Amin et al., 2013; Diamanti et al., 2008; Elfvin et 
al., 2015; Tappenden, 2014).  
These adaptations are thought to be largely mediated by glucagon-like peptide-2 (GLP-
2), an intestinotrophic hormone that works intimately with insulin-like growth factor 1 (IGF-1) 
(Dubé et al., 2006). GLP-2 is secreted from enteroendocrine L-cells in the intestinal mucosa, 
which in turn stimulates expression of IGF-1 in the intestine and liver. Basal levels of GLP-2 are 
high in premature compared to full-term infants, indicating its role in the final stages of intestinal 
development before birth (Amin et al., 2008). Bowel resection itself stimulates a higher secretion 
of GLP-2 (Matarese, 2013; Naberhuis & Tappenden, 2015). Serum values of total GLP-2 are 
higher in patients with residual colon, indicating that it is an important site of GLP-2 secretion; 
therefore, development of treatments that stimulate GLP-2 secretion and accelerate progression 
to enteral autonomy is key. 
 
1.1.3 Treatments That Enhance Intestinal Adaptation in Children 
 Enteral feeding of hypocaloric enteral nutrition (EN), also referred to as trophic feeding 
or minimal EN, in combination with PN can help stimulate intestinal adaptation through 
stimulation of blood flow, release of biliopancreatic secretions, enhancement of the local 
immune system, and promotion of commensal bacterial growth (Andorsky et al., 2001; Quirós-
Tejeira et al., 2004; Roy et al., 2014). Complete lack of enteral stimulation can lead to further 
atrophy of the remaining intestine, clearly in opposition to weaning from PN and achievement of 
enteral autonomy. Furthermore, a standardized, slow enteral feeding protocol may reduce the 
incidence and mortality rate of NEC, especially for infants with the lowest birth weights 
(Viswanathan et al., 2015), demonstrating its utility during the entirety of the disease process. 
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Rate of EN infusion is an important consideration. Continuous feeding offers increased 
tolerance and absorption, but potential small bowel bacterial overgrowth (SIBO). Alternatively, 
bolus feeding provides normal gut hormonal stimulation but increased potential for 
malabsorption and osmotic diarrhea (Andorsky et al., 2001; Quirós-Tejeira et al., 2004; Roy et 
al., 2014).  
It is also important to consider which enteral formula to use. Breast milk is the preferred 
food for pediatric EN, given its ability to reduce total days on PN and extensive, unique trophic 
factors and bioactive components (Hendricks & Guo, 2014) that are not typically found in 
formula. However, since breast milk is not always available from the mother or donors, partially 
hydrolyzed high-quality protein formulas (as 20% of total calories) may be implemented 
(Andorsky et al., 2001; Matarese, 2013; Roy et al., 2014). High-fat formulas (up to 50% of total 
calories, as tolerated) formulated with long-chain fatty acids and supplemented with essential 
fatty acids are recommended due to their high energy density, tendency to reduce motility, and 
moderate risk of essential fatty acid deficiency in this population. Complex carbohydrates should 
be rich in the diet due to their high digestibility (50-60% or 40-50% of energy depending on 
whether or not the patient has remaining colon) but simple carbohydrates should be avoided due 
to their tendency to increase osmotic diarrhea. Overall, direct mechanical and chemical 
stimulation of the remaining intestine presents a cheap and feasible approach to encouraging 
intestinal adaptation, albeit somewhat technical to administer and formulate. 
Teduglutide (a GLP-2 analogue that resists enzymatic inactivation) is a safe and 
efficacious drug approved for use in adults with intestinal failure (Naberhuis & Tappenden, 
2015). Trials in infants were limited to preclinical animal models (Naberhuis, Deutsch, & 
Tappenden, 2015; Thymann et al., 2014) until very recently. These studies demonstrate acute 
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structural adaptations in all segments, but the more limited functional adaptations in the small 
intestine. 
Pre-, pro-, and synbiotic therapies are promising new options for preventing IF or 
stimulating intestinal adaptation once it has occurred. The commensal intestinal microbiota 
represent a medium through which to stimulate intestinal adaptation via their ability to influence 
nutrient availability, enteroendocrine function, barrier function, and immunity.  
Clinical trials have investigated the ability of probiotics to prevent NEC, which would 
reduce development of SBS. Twenty-six studies which evaluated the efficacy of probiotics to 
prevent NEC or lessen severity of the disease were analyzed in a single meta-analysis (Aceti et 
al., 2015). Neither Lactobacillus rhamnosus GG nor L. reuteri examined individually altered 
NEC incidence, but pooling all studies that utilized Lactobacillus spp. displayed a 0.62 relative 
risk (RR), that tended to be significant at P = 0.07. Bifidobacterium lactis administration 
conveyed a 0.23 RR (P = 0.0008) and pooled Bifidobacterium spp (lactis, breve, and bifidum) 
administration conveyed a 0.24 RR (P = 0.0006). Sachharomyces boulardii had no effect. Pooled 
analysis of all twenty-six studies yielded a RR for NEC of 0.47 (P < 0.00001). Overall, 
probiotics may be effective at preventing or reducing the severity of NEC, but Bifidobacterium 
spp. may represent the most effective option. 
Very little research has been conducted to test the efficacy of pro- and synbiotics in 
attenuating the symptoms of SBS. None of these studies directly measured markers of intestinal 
adaptation, but some insight into changes elicited in the microbial population were gleaned. 
Probiotic Lactobacillus rhamnosus GG (LGG) administered as 109 cells/capsule to children with 
SBS resulted in no changes to intestinal permeability and an increase in total Lactobacillus only 
in patients with relatively low basal levels (Sentongo et al., 2008). In a different study, synbiotic 
	 6 
Bifidobacterium breve with Lactobacillus casei (>109 cfu total) and 1g galactooligosaccharides 
administered three times daily over a year resulted in a shift from a predominantly facultative 
anaerobic to anaerobic microbiota, including increased total Bifidobacterium and Lactobacillus 
(Kanamori et al., 2004; Uchida et al., 2007). Furthermore, average total fecal short-chain fatty 
acids were increased (27.8 to 65.1 μmol/g wet feces) and body weight gain was accelerated in all 
but one subject. 
Bearing these microbial shifts in mind, careful consideration should be given each 
patient’s medical history when considering microbiota-based interventions. A complication of 
SBS, D-lactic acidosis, occurs when the intestinal microbiota produce an amount of D-lactate 
that overcomes the ability of the microbial community, the host’s intestine, liver, and kidneys to 
metabolize it (Kowlgi & Chhabra, 2015). In a pediatric SBS case study, repeated episodes of D-
lactic acidosis was attributed to administration of combined Lactobacillus acidophilus and 
Bifidobacterium spp. (Ku, Lau, & Huen, 2006).  Conversely, D-lactic acidosis was normalized 
and prevented in a 28-year-old man with SBS who received B. breve and L. casei with 1g 
galactooligosaccharides 3 times daily (Takahashi et al., 2013). This sparse evidence highlights 
the high inter-individual variability associated with modulation of microbiota in patients with 
SBS. 
Fortunately, testing of prebioitc and probiotic therapy in pre-clinical animal models 
provides more insight into their effects on intestinal adaptation. In rat models of SBS, probiotic 
treatment with Lactobacillus rhamnosus GG or Bifidobacterium lactis causes a reduction of 
bacterial translocation across the gut epithelium, decreased enterocyte apoptosis, and increased 
markers of structural adaptation in the ileum and jejunum including: mucosal and whole organ 
weight, mucosal DNA and protein, villus height, and crypt depth compared to SBS control 
	 7 
(Eizaguirre et al., 2002; García-Urkia et al., 2002; Mogilner et al., 2007). By contrast, a cocktail 
of Lactobacillus acidophilus, Bifidobacterium spp, and Streptococcus thermophiles administered 
to rats with SBS only conveyed benefits to the jejunum (increased villus height, crypt depth, and 
immunohistochemical cells) but not the ileum (Tolga et al., 2011). As illustrated by the inferior 
benefits of multi-species treatment (which included species similar to those used individually) an 
understanding of how probiotic species work together and convey their benefit is needed. 
One study has investigated the effects of pre-, pro-, and synbiotics side-by-side in a 
neonatal model of intestinal failure (Barnes et al., 2012). Prebiotic scFOS at 10 g/L increased 
ileal mucosal weight and protein, jejunal glutamine and peptide transport, and colonic glutamine 
transport. Both scFOS and synbiotic (scFOS+ 109 cfu LGG) treatment increased ileal villus 
length and epithelial proliferation. Probiotic alone had no effect. It is interesting to note that the 
addition of LGG to the scFOS treatment (synbiotic) abolished some of the functional adaptations 
conveyed by scFOS alone, again indicating the need for an understanding of how pre- and 
probiotic treatments interact in vivo. 
The mechanisms by which pre-, pro-, and synbiotic therapies convey potential benefits 
and risks to infants with SBS is still poorly understood, especially in terms of how pre- and 
probiotics act in combination to modulate the indigenous microbiota-specific to each host. 
Further investigation into these mechanisms (in vivo and in vitro) requires further investigation. 
 
1.2 LEVERAGE OF THE INTESTINAL MICROBIOME 
The microbiota of the gastrointestinal tract is an integral part of our growth, development, 
and health from the time that we are born. Their importance is related to their abilities to 
metabolize compounds in ways that we cannot, protect the epithelial layer with the largest 
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surface area in the body, and stimulate tissue growth – all of which can be leveraged to stimulate 
intestinal adaptation. 
 
1.2.1 Acquisition and Composition in the Infant 
Infants are born with a nearly uncolonized gastrointestinal tract, minus those species that 
may already present –albeit controversially- in the placenta, umbilical blood, and amniotic fluid 
(Aagaard et al., 2014). This does not last long, as the baby collects bacteria (mostly 
Lactobacillus and Prevotella) as it exits the birth canal (Dominguez-BelIo et al., 2010). 
Alternatively, babies born via cesarean section collect their initial microbes from the hospital 
environment, those being from genera generally found on the skin (mostly Staphylococcus, 
Corynebacterium, and Propionibacterium) (Schwiertz et al., 2003). These lineages are thus 
reflected in the oral cavity and meconium. 
In the first weeks of life, drastic changes and wild fluctuations in the abundance of 
gastrointestinal taxa occur. Lineages from less certain origins interact and overtake the microbes 
present at birth, generally beginning with facultative anaerobes (Enterobacteriaceae, 
Staphylococcus, and Streptococcus), which assumedly prime the environment for a shift to strict 
anaerobes (Eubacterium and Clostridium) perhaps even in the first few days (Jost et al., 2012; 
Palmer et al., 2007). 
Breast versus formula feeding of infants concurrently impacts the development of the 
intestinal microbiota, demonstrating another reason why choosing which food should be 
delivered via the lumen can have a large impact on infants with IF. While some inconsistencies 
exist in the literature, recent studies examining fecal bacterial 16s sequences reveal an early 
predominance of Bifidobacterium in both groups, higher Bacteroidetes in breast fed but higher 
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Firmicutes in formula-fed, and intricate changes unique to the composition of the milk and 
formula that the infant is receiving, but no overall differences in diversity (Jost et al., 2012; 
Tannock et al., 2013; Wang et al., 2015). These changes are attributed to basic components of 
the two foods such as protein and simple carbohydrate, but also the unique components of human 
breast milk including human milk oligosaccharides (HMO), immunoglobulins, nucleotides, 
lysozyme, lactoferrin, and even live bacteria similar to those found in the mother’s intestines 
(Cabrera-Rubio et al., 2012; Jost et al., 2014). Commercially available infant formulas continue 
to make progress towards mimicking some feasible aspects to bring it closer to the complex 
composition of human milk, such as the addition of HMO, but a perfect substitute is still far off. 
The microbiota continues to change through the events of weaning (as solid, more varied 
food is introduced), puberty, illness, and development until a more stable -yet still modifiable- 
adult-like composition is reached. All of these factors introduce variability in the development of 
microbiota in infants with SBS, since mode of delivery, limited consumption of breast milk, 
isolation from other humans, and occurrence of further medical complications create diversion 
between patients. 	
1.2.2 Dietary Modification 
Dietary factors other than feeding human milk or formula are capable of modulating the 
composition and activities of the infant’s intestinal microbiota, namely: prebiotics, probiotics, 
and synbiotics. Although currently debated, the current definition of prebiotic is generally 
accepted as “a non-digestible food ingredient that beneficially affects the host by selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in the colon” 
(Schrezenmeir & De Vrese, 2001). 
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Scientists seek to expand this definition to include which food ingredients, benefits, and 
specific bacteria and activities, but with an ever-growing list of potential prebiotic compounds 
including: inulin, fructooligosaccharides (FOS), galactooligosaccharides, lactulose, polydextrose, 
isomaltooligosaccharides, xylooligosaccharides, lactilolarabinoxylooligosaccharides, mannitol, 
maltodextrin, raffinose, HMO, sorbitol, resistant starch, pectin, β-glucans, and still others, the 
solution is not straight forward (Patel & Goyal, 2012). 
FOS, particularly scFOS administration in infants has been investigated for its 
bifidogenic (Paineau et al., 2014; Ripoll et al., 2015), propiogenic and butyragenic (Shen et al., 
2011), and immunostimulatory (Paineau et al., 2014; Ripoll et al., 2015) effects. It is also well 
tolerated by the pediatric population, including those with SBS (Khoshoo, Sun, & Storm, 2010; 
Ripoll et al., 2015). Additionally, the lower degree of polymerization (compared to inulin and 
other FOS) is an advantage in SBS, as it is more likely to be completely fermented in the 
shortened length of intestine. These benefits make scFOS a good candidate for stimulating 
intestinal adaptation. 
scFOS was tested by Barnes and colleagues in a pre-clinical neonatal piglet model of 
SBS with promising results (Barnes et al., 2012). After 80% small bowel resection, the addition 
of scFOS to partial EN promoted structural and functional adaptations in less than a week. 
These benefits are not without possible risk. Recall that individual responses to treatment 
should be considered, especially with respect to dosage, and that D-lactic acidosis is a potential 
complication of bacterial dysbiosis in SBS. In a prebiotic and probiotic trial, high amounts of 
FOS (100g/kg) fed to rats induced hyperlactate production (Hashizume et al., 2003). This state 
was resolved with the administration of Megasphaera elsdenii, leading to decreased lactate and 
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increased butyrate concentrations. While promising, scFOS supplementation should be 
approached with careful attention to both dose and complimentary probiotic. 
Probiotics are “live microorganisms that when administered in adequate amounts confer a 
benefit to the host.” (Schrezenmeir & De Vrese, 2001) While traditionally Lactobacillus and 
Bifidobacterium spp. have been investigated for their probiotic effects, recently Streptococcus, 
Bacteroides, Ruminococcus, Lactococcus, Enterococcus, and species from other genera have 
been investigated and made commercially available worldwide. 
LGG is designated ‘generally recognized as safe’ by the FDA and is therefore widely 
administered in both infant and adult populations. Its propensity to reduce allergies (Nermes et 
al., 2011), decrease pathogen-induced diarrhea (Davoodabadi et al., 2015), and in some cases 
increase butyrate-producing bacteria (Canani et al., 2015) has been explored in infants. However, 
these changes may not be associated with a change in bacterial diversity (Ismail et al., 2012), 
which is often cited as an indicator of a “healthier” microbiome. 
LGG was tested alongside scFOS in the Barnes an colleagues 2012 trial with less 
appreciable structural and functional adaptations, especially compared to the prebiotic treatment 
(Barnes et al., 2012). Administration of LGG with scFOS as a synbiotic therapy negated some of 
the functional adaptations elicited by scFOS alone. 
Pre-, pro-, and synbiotic therapy can confer benefits to infants, but “one-size-fits-all” and 
“can’t have too much of a good thing” approaches will not work. Only by understanding how 
prebiotics and probiotics affect microbial syntrophy and their interaction with the host can an 
effective synbiotic therapy be developed. 
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1.2.3 Microbial Metabolism 
 To understand how members of the intestinal microbiota interact with one another as well 
as respond to prebiotic and probiotic treatments, one must understand their metabolism.  The 
human microbiome (the majority of which resides within the gastrointestinal tract) has been 
equated to a postnatally acquired organ (Clarke et al., 2014; O'Hara & Shanahan, 2006) with a 
cellular quantity ten times higher and genetic capacity hundreds of times higher than that of our 
cells. Unsurprisingly, the majority of these genes and their functions remain uncharacterized 
(Huttenhower et al., 2012). It is known, however, that microbes possess a diverse array of 
enzymes that are readily mobilized upon contact with the substrate (Dodd & Cann, 2009; Zhang 
et al., 2014). These residents have co-evolved with us to extract energy and further metabolize 
substrates resistant to mammalian digestion and absorption and endogenously secreted intestinal 
components (Egert et al., 2006). These compounds include: microbially accessible 
carbohydrates, dietary and endogenous proteins, fatty acids, mucins, sloughed epithelial cells, 
and intermediates of inter-microbial metabolism. The vast majority of this metabolism takes 
place anaerobically through the processes of microbial fermentation, creating short-chain fatty 
acids (SCFA), lactate, and other organic acids. 
 Digestion of prebiotics highlights the intestinal microbiota’s ability to utilize substrates 
that mammals cannot. In the case of scFOS and other FOS, three major genera possess the beta-
fructofuranosidases (βFFase) required to begin their digestion, namely: Bacteroides, 
Lactobacillus, and Bifidobacterium (Goh & Klaenhammer, 2015; Van Meulen, et al., 2006). 
However, the mechanism by which these genera execute digestion of scFOS differs, and thus has 
a large impact on the metabolic fate of the resulting substrates. The majority of Lactobacillus and 
some Bifidobacterium species rely on membrane-anchored βFFase or intracellular βFFase to 
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digest scFOS after it has been transported into the cell. In this way, only the excreted, final 
metabolites (primarily lactate and acetate) are available to the microbial community at large. 
Conversely, Bacteroides species tend to express more extracellular βFFase, which then provides 
oligo- and monosaccharides as well as various final metabolites to its community. This 
difference likely explains why some Bifidobacterium spp. (and by proxy Lactobacillus spp.) can 
outcompete Bacteroides spp. in co-culture with inulin as the substrate (Falony et al., 2009). 
 SCFA are the primary end-product of microbial fermentation of carbohydrate (Den 
Besten et al., 2013). These saturated organic acids exert beneficial metabolic effects on the host, 
regulate local gene expression, and stimulate the enteroendocrine system. It is estimated that 
SCFA contribute approximately 10% of an individual’s daily estimated energy requirement, 
dependent on the type and amount of fiber consumed (Bergman, 1990). The typical ratio of 
acetate:propionate:butyrate (60:20:20) in the colonic digesta as well as their absolute abundance 
can be shifted by dietary factors, especially fiber and prebiotics. Each SCFA elicits shared and 
unique responses from the host, but also plays roles in the balance and formation of other SCFA 
and organic molecules. 
 Acetate, the most abundant SCFA, is associated with increased fermentation efficiency 
(Den Besten et al., 2013; Macfarlane & Macfarlane, 2011). Relevant to the treatment of SBS, 
higher relative acetate production following prebiotic administration is associated with 
concurrent increases in lactate and butyrate in vitro (Li et al., 2012; Macfarlane & Macfarlane, 
2011). Higher energy harvest from carbohydrate that would otherwise be inaccessible benefits 
infants with SBS, due to the high energy demands associated with healing and growth, which are 
compounded by malabsorption. In monogastric mammals, the major metabolic fate of absorbed 
acetate is conversion to acetyl-CoA for lipogenesis in the liver (as in humans) or adipose (as in 
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pigs). Effects of acetate on the intestine have been investigated by profusion in live animals 
(Scheppach, 1994). Beneficially, acetate elicits increased colonic blood flow, but also increased 
ileal motility. However, decreased transit rate and thus increased time for nutrient digestion and 
absorption is desirable in infants with SBS.  
Studying sources of microbially produced acetate in the intestine is complicated, as 
acetogenic pathways are widely distributed among intestinal bacteria. However, possession of 
the acetyl-CoA synthase gene is considered an appropriate genetic marker of major acetogens in 
the intestine (Gagen et al., 2010).  
 Propionate, the second most abundant SCFA, benefits the intestine by regulating 
differentiation, proliferation, and apoptosis of crypt cells (Hosseini et al., 2011). Most absorbed 
propionate is transported to the liver, where it enters the TCA cycle through oxaloacetate 
(Bergman, 1990). It is produced through one of three pathways by the gastrointestinal microbiota 
(Reichardt et al., 2014). The acrylate and propanediol pathways (utilizing lactate and deoxy 
sugars respectively) are less abundant than the dominant succinate pathway, which utilizes 
hexose and pentose sugars to produce propionate. Interestingly, some bacteria such as 
Coprococcus catus, Megasphaera elsdenii, and Roseburia inulinivorans can shift between 
butyrate and propionate production on different substrates. 
 Butyrate, the third most abundant SCFA, is the preferred energy source of colonocytes, 
providing 60-70% of their total energy, hence why the majority of absorbed intestinal butyrate 
does not reach the liver and is usually undetectable in peripheral circulation (Bergman, 1990; 
Macfarlane & Macfarlane, 2011). It has been widely studied for its multiple benefits to the 
intestine, which include: modulation of the immune system, regulation of proliferation, 
differentiation, and apoptosis; enhancement of nutrient absorption, and improvement of barrier 
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function and mucin gene expression (Bergman, 1990; Den Besten et al., 2013; Scheppach, 1994; 
Tappenden et al., 1998). 
Butyrate-producing bacteria are a heterogenous and widely phylogenetically diverse 
group of Gram-positive, anaerobic bacteria (Louis & Flint, 2009; Vital, Howe, & Tiedje, 2014). 
The major pathway of butyrate production by intestinal bacteria is through butyryl-CoA:acetate-
CoA transferase (BCoAT) and to a much lesser extent through butyrate kinase (Louis et al., 
2004). Through the BCoAT pathway, bacteria preferentially utilize exogenous lactate (Sato et 
al., 2008) and acetate (Duncan et al., 2004) to produce butyrate and acetyl-CoA (Louis & Flint, 
2009). However, in vitro experiments demonstrate that when pH falls below 5.2 neither butyrate 
nor propionate are formed by human fecal cultures, potentially from lactate toxicity (Belenguer 
et al., 2007). Butyrate (but not propionate) production was restored at pH 5.9, also normalizing 
lactate concentrations. In the same study, polysaccharide supplementation yielded higher 
butyrate production over propionate, but addition of lactate alone reversed this hierarchy. 
Similarly in human in vitro cultures, relatively higher peptide concentration (0.6% vs 0.1%) and 
lower pH (5.5 vs 6.5) yielded higher butyrate production and increased butyrate-producing 
Roseburia spp. abundance while the converse conditions yielded higher propionate and 
Bacteroides spp. (Walker et al., 2005) These data imply that maximal butyrate production 
requires a balance of optimal pH, substrate availability, and inter-species relationships. This may 
be difficult to establish in the compromised gut ecosystem of SBS, but the many intestinal 
benefits that butyrate conveys make it a worthy target. 
Lactate is a primary end product of fermentation by lactic acid bacteria, including 
Lactobacillus and Bifidobacterium (Garvie, 1980; Kandler O., 1983), which are generally 
thought of as beneficial to the intestine. Terminal lactate production is performed by lactate 
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dehydrogenase (LDH), which converts pyruvate to lactate. Different forms of LDH produce D- 
and L-isomers of the compound. While L-Lactate is readily metabolized by the intestine and 
liver, D-lactate has no known dedicated enzymatic pathway for its metabolism. This contributes 
to D-lactic acidosis, for which patients with SBS are at risk. 
Syntrophy is the phenomenon in which microbial metabolites are taken up and 
metabolized by other members of the community. Lactate, for example, does not accumulate in 
healthy individuals as other microbes quickly utilize it, including many butyrate-producers 
(Diez-Gonzalez et al., 1999; Louis & Flint, 2009; Muñoz-Tamayo et al., 2011; Vital et al., 2014). 
Lactate-utilizing bacteria often perform the reverse reaction to produce pyruvate from lactate, 
which then enters core energy metabolism. An in vitro fermentation test in piglet fecal inoculum 
revealed the highest levels of total SCFA production occurred with supplementation of DL-
lactate mixture over either isoform alone (Su, Li, & Zhu, 2013). Furthermore, either isoform 
supplemented alone displayed shifts in several taxa that contrast those of the other isoform, 
including those of known butyrate-producers. Specifically, supplementation of D-lactate tended 
to support the growth of Lachnospiraceae whereas L-lactate tended to support the growth of 
Coprococcus and Subdoligranulum. This type of specialization may reduce competition and 
contribute to the overall diversity of the microbiota. Conversely, an environment that fosters over 
or underproduction of either isoform may lead to dysbiosis and lower total SCFA production. 
Bifidobacterium and Bacteroides are recognized as commensal bacteria with extensive 
carbohydrate digesting enzyme repertoires (Rossi et al., 2005; Terrapon & Henrissat, 2014). In 
this sense, these genera contribute to syntrophy by liberation of smaller carbohydrates and 
excretion of metabolic intermediates (such as lactate from Bifidobacterium) (Belenguer et al., 
2006; Wexler, 2007). 
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Degradation of complex endogenous compounds such as mucous begins another 
significant pathway of syntrophy (Deplancke & Gaskins, 2001; Marcobal et al., 2011). The 
variety of glycan moieties found in mammalian mucins (especially in humans) are resistant to 
degradation by both endogenous and microbial enzymes. Many opportunistic pathogens, such as 
enteropathogenic Escherichia coli, begin their invasion by compromising this innate protection 
(Croxen & Finlay, 2010). However, some commensal organisms like those in the Bacteroides 
and Ruminococcus genera can strike a balance and degrade an amount of mucus that is 
acceptable to the host, liberating small carbohydrates that are utilizable by other beneficial 
genera, such as Bifidobacterium (Tailford et al., 2015). Understanding the intricate interplay of 
taxa, metabolites, and gut environment that shapes SBS will reveal important targets that can 
minimize dysbiosis while optimizing production of health-promoting compounds such as 
butyrate. 
 
1.2.4 Alteration of Nutrient Digestion and Absorption 
 The central problem for patients with SBS is the inability to digest and absorb enough 
nutrients to sustain life and support growth. Therefore, the intestinal microbiota’s ability to 
modulate the host’s digestion and absorption of nutrients is of vital concern. Microbial 
metabolites, enzymatic activities, and pathogenic factors impact the way that the intestine 
interacts with nutrients through its membrane and various transporters. 
 With a shortened intestinal tract, the absorption of water and electrolytes becomes more 
important for infants with SBS. The microbiota can help or hinder this process. Positively, the 
absorption of SCFA concurrently increases the absorption of water and electrolytes by both 
drawing them across the membrane and increasing the expression of sodium-proton exchanger 
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NHE3 (Musch et al., 2001; Schmitt, Soergel, & Wood, 1976). Negatively, many opportunistic 
pathogens such as enteropathogenic Escherichia coli induce decreased expression of NHE3 and 
electrolyte absorption, decrease epithelial surface area through attaching and effacing, and 
induce diarrhea that removes water, electrolytes, and SCFA from the intestinal lumen (Hodges & 
Gill, 2010; Moon et al., 1983).  
 Another mechanism through which the microbiota could alter nutrient transport is 
through glycosylation of nutrient transporters. Changes in multiple glycosylation sites of sodium-
glucose co-transporter 1 (SGLT1) and peptide transporter 1 (PepT1) result in changes in 
transporter activity (Arthur et al., 2014; Daniel & Stelzl, 2016). While no evidence exists that 
microbial enzymes do alter glycosylation sites of nutrient transporters, the extracellular location 
of many of the glycosylation sites on nutrient transporters and vast array of microbial 
glycosylation enzymes lends this as a possibility. 
 
1.2.5 Short-Bowel Syndrome Associated Microbiota 
To make a prediction about how a microbe-focused intervention might affect changes in 
the microbial community and how it interacts with the intestine, it is helpful to understand what 
the usual composition of the intestinal microbial community in patients with SBS is like. Few 
studies have fully assessed the microbiota of children (Engstrand Lilja et al.,  2015; Korpela et 
al., 2015) and adults (Joly et al., 2010) with SBS, but none have described the microbiota of 
infants with SBS. A common theme emerges from these studies indicating Lactobacillus 
overabundance and reduced bacterial diversity. Studies in children also revealed enrichment of 
Proteobacteria, associated with prolonged PN dependence, liver steatosis, and intestinal 
inflammation. 
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In a pre-clinical animal study, piglets with 75% small bowel resection were observed for 
6 weeks post-operation. By the end of the study, microbial dysbiosis was demonstrated by 
reduced colonic bacterial diversity, decreased Bacteroidetes, increased Fusobacteria, and an 
increased Firmicutes:Bacteroidetes vs control (Lapthorne et al., 2013). 
 
1.2.6 Microbial Diversity and Disease States 
But what are the implications of dysbiosis and decreased diversity in patients with SBS? 
Lower microbial diversity is generally associated with poorer individual health, as it has been 
observed in disease states such as diarrhea (Mai et al., 2006; Youmans et al., 2015), colon cancer 
(Gao et al., 2015), inflammatory bowel disease (Kabeerdoss et al., 2015; Li et al., 2012), obesity 
(Dominianni et al., 2015), and most others. Conversely, dietary habits associated with health 
such as increased fiber, fruit and vegetable, and whole grain intake increase diversity 
(Dominianni et al., 2015; Walter, Martínez, & Rose, 2013) and are associated with reduced 
incidence of disease. 
Lower abundance species may have higher influence on health than their higher-
abundance counterparts. Increased diversity of lower abundance species creates higher resilience 
to disturbances such as antibiotic use (Dethlefsen & Relman, 2011) and fiber supplementation 
(Duncan et al., 2007). It is notable that butyrate-producers fall into this category, as each species 
represents <10% of the entire intestinal population (Louis & Flint, 2009). Supporting this idea, 
higher butyrate production is associated with higher microbial diversity (Le Chatelier et al., 
2013). 
It is more difficult to gauge stability against major, permanent insults such as chronic 
disease. In transient cases of diarrhea and antibiotic use, individuals tended to shift back towards 
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their original community after the insult was removed. However, not all individuals completely 
returned to baseline. In the case of obesity, weight loss does result in a more “lean-type” 
microbiota, but whether or not this resembles their pre-obesity community is unknown (Remely 
et al., 2015). Similarly, restoration of a “normal” microbiota following intestinal adaptation also 
remains unknown. 
 
1.3 BARRIER FUNCTION INTERACTIONS 
As the largest epithelial barrier of the body, the intestine must permit the absorption of 
nutrients while restricting the entry of bacteria, toxins, and other pathogens (Groschwitz & 
Hogan, 2009). Surgical resection of the intestine resulting in SBS creates alterations in structure 
and function, thus impairing the ability of the intestine to exercise this selectivity (Tappenden, 
2014). Therapies for infants with SBS primarily focus on stimulating intestinal adaptation with 
respect to digestion and absorption, while barrier function has been a lesser focus. However, 
incidence of bloodstream infection due to bacterial translocation affects an estimated 46-80% of 
infants hospitalized with SBS (Cole et al., 2010; Miko et al., 2015), while D-lactic acidosis 
remains an under-recognized and often undiagnosed problem in this population (Kowlgi & 
Chhabra, 2015). This highlights the need to develop therapies that will address conditions related 
to impaired intestinal integrity and nutrient processing concurrently. 
As the intestine heals and adapts, tight junctions must be broken and restructured while 
goblet cells react to signals from both microbiota and the rest of the organ to modify mucin 
expression and secretion. Meanwhile, reduced length and nutrient processing capacity of the 
remaining intestine generates the need for the distal intestine to facilitate digestion and 
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absorption of nutrients that would normally be processed in the proximal intestine. How these 
processes work together to maintain homeostasis following major intestinal insult requires study. 
 
1.3.1 Goblet Cells and Mucins 
Goblet cells produce, post-translationally modify, and secrete mucins. These mucins 
serve to coat and protect the intestinal epithelium from passing digesta and microbes, which 
modify and digest mucins in turn (Deplancke & Gaskins, 2001). Two major subtypes of mucins 
exist: secretory mucins secreted by goblet cells to form a gel at the epithelial surface (including 
MUC2 and rarely MUC5AC in the intestine) and membrane-anchored mucins inserted into the 
apical membrane of both goblet and absorptive cells (MUC1, MUC3, MUC4, and MUC13 in the 
intestine) (Kim & Ho, 2010). 
In order to function properly, these protein backbones are extensively glycosylated, 
including sulfation, fucosylation, galactation, sialylation, and others - the extent of which varies 
along the length of the intestine (Bergstrom & Xia, 2013; Robbe et al., 2003). These 
modifications create an acidomucin chemotype, which is more resistant to microbial degradation 
– especially in the case of sulfation (Conour et al., 2002). Furthermore, the observation that 
acidomucins are abundant in the intestine at the end of fetal development supports the protective 
nature of these molecules. 
Other important products of goblet cells contribute to the defense and maturation of the 
intestinal epithelia. Intestinal trefoil factor (TFF3) is the second most abundant product of mature 
goblet cells (after MUC2), which aids in epithelial restitution and works with mucus to enhance 
barrier function (Kim & Ho, 2010). Investigation into these mechanisms indicates that TFF3 
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facilitates cellular migration and inhibits apoptosis, with no effect on proliferation. Furthermore, 
mucosal protection is enhanced through scaffolding with MUC2, increasing mucus viscosity. 
Another such product of goblet cells is resistin-like molecule beta (RELMβ). RELMβ 
serves an immunoregulatory function through cytokines IL-4 and IL-13 (Kim & Ho, 2010). In 
terms of barrier function, RELMβ upregulates transcription and secretion of MUC2. Together, 
these mechanisms increase expulsion of intestinal parasites, as demonstrated in bacterial and 
nematode infection in mice (Herbert et al., 2009). Altogether, inducing secretion of mucins and 
other compounds from goblet cells may be beneficial to protecting the adapting intestinal 
epithelium in infants with SBS. 
 
1.3.2 Tight Junctions 
Intestinal epithelial cells adhere to one another by forming tight junctions in different 
combinations of zonula occludins, claudins, and occludins (Ulluwishewa et al., 2011). Tight 
junctions are further modulated by matrix metalloproteinases (Parks, Wilson, & López-Boado, 
2004), which are secreted by resident cells of the epithelium, as well as immune cells migrating 
through the tissue (Medina & Radomski, 2006). 
 The effect of probiotics on markers of barrier function in gastrointestinal diseases has not 
been widely studied in vivo (Ghouri et al., 2014; Mennigen & Bruewer, 2009). Of the few animal 
and human trials that exist (including a population of infants with SBS), most show no effect or 
have not been reproducible. However, in a gnotobiotic mouse model of dextran sodium sulfate-
induced colitis, Lactobacillus acidophilus increased the expression of cecal occludin while 
decreasing bacterial translocation and Escherichia coli Nissle 1917. This slso increased colonic 
expression of ZO-1 while reducing epithelial Evans blue uptake. As previously stated, Barnes 
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and colleagues 2012 examined the effect of LGG in a neonatal piglet model of SBS, with the 
only marker of barrier function measured – transepithelial electrical resistance (TER) – being 
decreased in the colon (Barnes et al., 2012). 
 The effects of prebiotics in vivo on markers of barrier function in intestinal disease are 
also an understudied area. A few randomized, clinical trials have implemented prebiotic therapy, 
specifically scFOS and lactulose, in an attempt to improve barrier function in adults with 
inflammatory bowel diseases, with no apparent improvement (Ghouri et al., 2014). Barnes and 
colleagues also examined the effect of scFOS in a neonatal piglet model of SBS, which 
decreased TER in the jejunum but transiently increased TER in the ileum. 
 Matrix metalloproteinases are excreted by a multitude of immune cells, including: 
macrophages, T-cells, fibroblasts, eosinophils, and neutrophils. In turn, they elicit a variety of 
effects including: regulation of cell growth, triggering the release of growth factors, regulating 
apoptosis, altering cell motility, affecting immune responses, and modulating the bioactivity of 
cytokines and chemokines (Al-Dasooqi, Wardill, & Gibson, 2014; Medina & Radomski, 2006). 
In these ways, inflammatory responses (both functional and in response to pathogens) may 
mediate structural adaptation during SBS. This overall lack of evidence demonstrates the need to 
investigate further the many factors involved in maintaining appropriate intestinal selective 
permeability and defense during intestinal diseases in vivo, especially SBS. 
 
1.4 ENTEROENDOCRINE INTERACTIONS 
1.4.1 Enteroendocrine L-cells 
Less than 1% of the intestinal epithelium is composed of cells dedicated to 
enteroendocrine function (Gunawardene, Corfe, & Staton, 2011). Of these cells, L-cells are of 
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particular interest to the treatment of SBS for their ability to produce and secrete hormones that 
alter growth and motility of the intestine. They are located primarily in the jejunum, ileum, and 
colon of humans, pigs, and rats (Eissele et al., 1992; Hansen et al., 2013; Kaji et al., 2011) with 
density increasing into the distal ileum that either tapers off in the colon (as in rats) or continues 
to increase into the colon (as in pigs and humans). 
 L-cells are one of three known cell types in the body (located in the intestine, pancreas, 
and brain) that express the proglucagon gene (Tianru Jin, 2008). Tissue-specific post-
translational processing in intestinal L-cell yields glicentin, oxyntomodulin, and glucagon-like 
peptides 1 and 2 (GLP-1 and GLP-2), which are co-secreted. Due to this process, no glucagon is 
produced in the intestine as occurs in the pancreas. 
 
1.4.2 Glucagon-Like Peptide-2 
 GLP-2 induces many structural and functional adaptations in the small and large intestine 
(Burrin et al., 2002; Sinclair & Drucker, 2005). Therefore, increasing GLP-2 secretion is 
advantageous in the achievement of enteral autonomy. After its secretion from L-cells, GLP-2 
has a very short half-life of approximately 7 minutes, primarily due to its regulation by dipetidyl 
peptidase IV (DPP-IV). Specifically of interest to infantile SBS, DPP-IV activity is higher in 
infants when compared to that of adults. For these reasons, GLP-2 analogues and DPP-IV 
inhibitors have been pursued with much interest in the treatment of SBS. Teduglutide, a GLP-2 
analogue with a longer half-life, has already been discussed. 
 DPP-IV inhibitor MK-0626 induced higher proliferation, villus length, and crypt depth in 
the jejunum and ileum of mice following 50% small intestinal resection (Sueyoshi et al., 2014). 
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Other DPP-IV inhibitors have been studied, but mostly in the context type II diabetes, thus 
markers of intestinal adaptation were not measured. 
GLP-2 signaling works through the GLP-2 receptor (GLP-2R), which has been identified 
in stomach, intestine, brain, lung, enteroendocrine, enteric neuronal, and subepithelial 
myofibroblastic tissues (Sinclair & Drucker, 2005). By acting upon cells associated with the gut, 
GLP-2 increases nutrient absorption, cellular proliferation and apoptosis, enteric blood flow, 
villus height, and crypt depth while also decreasing intestinal permeability and gastric motility. 
These effects have been extensively displayed in pre-clinical models of intestinal resection 
and/or chronic parenteral nutrition in pigs and rats (Burrin et al., 2005; Burrin & Stoll, 2000; 
Holst, 2000; Tappenden et al., 1998; Tappenden et al., 2003). 
 However, the growth effects of GLP-2 are dependent on insulin-like growth factor 1 
(IGF-1) and to a lesser extent IGF-2, as demonstrated in a knockout mouse models of IGF-1 and 
IGF-2 (Dubé et al., 2006). As these studies were performed in adult mice, it is unclear whether 
IGF-2 (which is most highly expressed perinatally) might play a more important role in intestinal 
growth in infants with SBS, especially those who are premature. 
 
1.4.3 Free Fatty Acid Receptors 2 and 3 
 Free fatty acid receptor (FFAR) 2, also known as GPR43, and FFAR3, also known as 
GPR41, are G-coupled protein receptors present in several cell types in the intestine (Kaji et al., 
2011; Karaki et al., 2008; Nøhr et al., 2013; Tazoe et al., 2009). While both receptors are found 
in L-cells, FFAR2 is also found in submucosal leucocytes, while FFAR3 is also found in 
submucosal and myenteric ganglia. It is currently unknown if the receptors are found on the 
apical, basolateral, or both membrane sites, and if this differs among different cell types. 
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 SCFA serve as ligands for both FFAR2 and FFAR3 receptors (Brown et al., 2003). 
Conflicting reports exist describing the affinity of FFAR2 and FFAR3 for different SCFA, 
potentially due to the use of different species in cell culture and in vivo studies (Le Poul et al., 
2003; Nian & Drucker, 1999; Nilsson et al., 2003; Nøhr et al., 2013; Tolhurst et al., 2012). 
FFAR2 is consistently highly stimulated by propionate, while acetate and butyrate might be of 
equal or lesser potency (propionate ≥ acetate ≥ butyrate). For FFAR3, propionate is higher or 
equal to butyrate, while acetate is many times less potent (propionate ≥ butyrate >> acetate).  
Upon activation of these receptors, the Gi/o (both FFAR2 and FFAR3) and Gq (only 
FFAR2) coupled pathways are activated, inhibiting cAMP production and causing increased 
cellular calcium concentrations respectively. In L-cells, the rise in calcium is associated with co-
secretion of GLP-1 and GLP-2 (Tolhurst et al., 2012). 
Prebiotic interventions have the ability to increase FFAR receptor abundance. Although 
the mechanism is not clear, feeding of a 5% FOS diet to rats for 28 days increased density of 
FFAR2 and GLP-1 positive L-cells in the proximal colon vs control (Kaji et al., 2011). 
Presumably these changes were due to increased SCFA concentrations, which were not 
measured. 
Many of the investigations of FFAR2 and FFAR3 have been with cell culture or lower 
resolution imaging, which has not provided a clear picture as to the normal cellular location of 
the receptors. Since luminal concentrations of SCFA are several orders of magnitude above the 
EC50 of both receptors, it is possible that they exist on the basolateral membrane, only sensing 
SCFA that have already been absorbed. Hence, absorption of SCFA may limit the FFAR 
mediated enteroendocrine response of L-cells. 		
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1.4.4 Competing Mechanisms 
 Two important biological processes potentially compete with enteroendocrine sensing of 
SCFA and nutrient processing: absorption of SCFA and increased intestinal motility. Rapid 
absorption of SCFA into circulation may reduce the likelihood of stimulating FFAR2 and 
FFAR3, depending on their cellular location, while increased motility may sweep SCFA and 
other nutrients away before they can be peripherally sensed or absorbed by the epithelium. 
Currently, SCFA are believed to be absorbed by two mechanisms of equal importance: 
passive diffusion and active transport. Unlike passive diffusion, which seems to exist at a 
consistent level, active transport can be modified by up-regulation of SCFA transporters, making 
this an important consideration in developing therapies for SBS. 
 Passive diffusion of SCFA can only occur when the SCFA are in the protonated and thus 
hydrophobic form (Bugaut, 1987). Up to 60% of SCFA are absorbed by this mechanism. The 
pKa of acetate (4.76) propionate (4.88) and butyrate (4.82) are much lower than the average pH 
of the colon (5.8-6.8). Thus much of SCFA would exist in the unprotonated form. However, the 
unstirred water layer present at the border of the mucosal membrane (~600μm thick in humans) 
is a more acidic microclimate due to H+ exchange into the lumen from enterocytes, allowing for 
a higher level of protonation, and thus passive diffusion of SCFA. 
 Active transport occurs in the intestine via monocarboxylate transporters and sodium 
monocarboxylate transporters, namely MCT1 and SMCT1 in the intestine (Halestrap & Wilson, 
2012).  Monocarboxylates include pyruvate, lactate, and SCFA, but not all substrates are 
equivalently preferred by each transporter. The two transporter types utilize different 
mechanisms to move molecules across the cell membrane.  
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MCT1 absorbs monocarboxylates through electroneutral anion exchange on a pH 
dependent basis, with over 4-fold higher butyrate absorption at pH 5.5 versus 8.0 (Ritzhaupt et 
al., 1998; Ritzhaupt et al., 1998). Additionally, all monocarboxylates compete for MCT1 
absorption, with inhibition rates between 30-50%. Incubation of colonic adenoma cell line 
AA/C1 in sodium butyrate increased expression of MCT1 mRNA and butyrate uptake, whereas 
these effects were not seen upon incubation of acetate or propionate (Cuff, Lambert, & Shirazi-
Beechey, 2002). This holds true in vivo, as piglets fed a 5% oat β-glucan diet for 14-days 
exhibited 40% and 50% increases in MCT1 mRNA expression in the cecum and colon 
respectively, which were positively correlated with butyrate and total SCFA concentrations 
(Metzler-Zebeli et al., 2012). 
SMCT1 (also known as SLC5A8) absorbs monocarboxylates through a sodium-coupled 
mechanism (Coady et al., 2004). Regarding SCFA, the affinity for SMCT1 is greatest for 
butyrate, followed by propionate, lactate, and acetate (butyrate > propionate > lactate > acetate) 
(Miyauchi et al., 2004). SMCT1 is distributed on the apical membrane of enterocytes with 
increasing abundance from the jejunum to the colon in rats and humans (Elangovan Gopal et al., 
2007; Iwanaga et al., 2006). It is likely that SCFA and/or other compounds associated with the 
gastrointestinal microbiota influence the expression of SMCT1, as the expression is greatly 
reduced in germ free mice. When these germ free mice were colonized with conventional 
microbiota, SMCT1 levels rose to match that of conventional mice (Cresci et al., 2010) 
Similar to FFARs, MCT1 and SMCT1 may have specific positions in enterocytes. It has 
been proposed that in intestinal epithelia, SMCT1 is expressed on the apical membrane and 
MCT1 on the basolateral membrane, necessitating coordination between the two transporters to 
increase net SCFA absorption into circulation (Halestrap & Wilson, 2012). However, these 
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SCFA and other nutrients may have a reduced chance to be absorbed if intestinal motility is high. 
A hormone influencing specifically intestinal motility is Peptide YY (PYY). 
PYY is also synthesized and secreted by enteroendocrine L-cells and acts on the 
intestinal tract to reduce motility and on the central nervous system to reduce appetite (Liu et al., 
1996). PYY is of particular interest for the treatment of SBS, due to its ability to increase transit 
rate, but also potentially increase colonic water and electrolyte absorption. 
 
1.5 CONCLUSIONS 
Improving treatment options for infants with SBS through the use of pre-, pro-, and/or 
synbiotics is no simple task, given the high variability in remaining intestinal tissue and intestinal 
microbiome from patient to patient, as well as the complexity of intestinal physiology. 
While some study has been conducted concerning pre- and probiotics in infants, much 
more is needed to understand the interactions between the microbiota and the intestine, 
especially in the context of SBS. However, these treatment options combined with potential drug 
therapies such as GLP-2 analogues and/or DPP-IV inhibitors holds great promise, as the few 
existing studies demonstrate their ability to enhance primarily structural adaptations in the mid 
intestine. 
Treatments that target butyrate production may hold the most benefit, given its robust 
ability to stimulate intestinal growth and increased nutrient processing. In order to refine such 
treatments, understanding the fermentation profile, site of fermentation, microbial syntrophy, and 
interplay of the different components of the enteroendocrine system is necessary. 
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Finally, how the intestine protects these newly remodeled structures and functions to 
retain its selective permeability should not be overlooked, given the comorbidities of this 
population. 
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CHAPTER 2: PREBIOTIC SHORT-CHAIN 
FRUCTOOLIGOSACCHARIDE DIFFERENTIALLY AFFECTS THE 
BUTYRATE-PRODUCING MICROBIAL COMMUNITY AND 
INTESTINAL NUTRIENT TRANSPORT WHEN SUPPLEMENTED 
WITH OR WITHOUT PROBIOTIC LACTOBACILLUS RHAMNOSUS 
GG IN PIGLETS WITH SHORT-BOWEL SYNDROME 
 
2.1 ABSTRACT 
 Manipulation of the intestinal microbiome is a logical target for the treatment of short-
bowel syndrome (SBS), given its ability to produce butyrate through microbial syntrophy. 
Herein, we investigated the effects of partial enteral nutrition supplemented with short-chain 
fructooligosaccharides (scFOS) and Lactobacillus rhamnosus GG (LGG) and interaction 
between the two on ileal and colonic butyrate and lactate-producing bacterial populations, their 
metabolite production, and their modulation of intestinal nutrient transport in a neonatal piglet 
model of intestinal failure. Piglets had surgical placement of a jugular catheter for delivery of 
parenteral nutrition, and an 80% jejunoileal resection of the small intestine to induce SBS. For 7 
days, subjects received enteral nutrition supplemented with: [1] nothing (CON), [2] 10g/L scFOS 
(PRE), [3] 109 colony forming units LGG (PRO), or [4] scFOS + LGG. Bacterial taxa were 
investigated via 16s sequencing. Nutrient absorption was measured ex vivo in modified Ussing 
chambers. scFOS increased chao1 alpha diversity as a main effect in the ileal digesta (P = 
0.0427) which was correlated to abundance of butyrate-producing species (TBP) (R2 = 0.598, P 
< 0.01). scFOS and SYN increased TBP in the ileal digesta (both P < 0.05), which was 
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associated with increased electrogenic glucose absorption (R2 = 0.477, P = 0.0529). The 
probiotic, LGG, was represented by a single OTU, which primarily colonized the ileal digesta. 
LGG, PRO, and SYN increased total Lactobacillus (TLB) in the ileal digesta (all P < 0.05), and 
PRO increased D-lactate producing Lactobacillus (P = 0.0712) with negative effects on ileal 
peptide absorption (R2 = -0.485, P = 0.0567). Neither β-Fructofuranosidase (BFFase) nor total 
Bacteroides were affected by treatment, but specific species including B. thetaiotaomicron, 
which was correlated with BFFase, were alternatively increased by treatments. Further 
investigation into butyrate-producing species through LEfSe and SparCC analyses indicated that 
each treatment created new niches for butyrate-producers unique to each treatment. This data 
demonstrates that overabundance of Lactobacillus, especially those that produce D-lactate, 
contraindicates the use of LGG with scFOS as a synbiotic combination. The increase in TBP and 
glucose absorption associated with scFOS reinforces its potential usefulness in the treatment of 
SBS. 
  
2.2 BACKGROUND 
Short-bowel syndrome (SBS) is a costly condition primarily affecting very low birth 
weight, premature infants with long-term detriment to nutritional adequacy (Roy et al., 2014) and 
quality of life (Kelly et al., 2014). Necrotizing enterocolitis (NEC) -the primary cause of surgical 
resection leading to pediatric SBS- has an ill-defined etiology which is associated with intestinal 
microbial dysbiosis (Neu & Walker, 2011), defined by altered intestinal microbiota, decreased 
bacterial diversity, and antibiotic use. Hence, manipulation of the intestinal microbiota is a 
logical target for the treatment of NEC and SBS.  
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Butyrate is a short-chain fatty acid (SCFA) product of microbial fermentation in the distal 
intestine, which conveys numerous benefits including regulation of: fluid and electrolyte 
balance, enteroendocrine hormone secretion, barrier function, inflammation, and provides the 
primary source of energy for colonocytes (Canani et al., 2011). Thus, butyrate represents a 
promising therapy for stimulating intestinal adaptation following surgical resection. While 
addition of butyrate to parenteral nutrition increases intestinal epithelial surface area and nutrient 
absorption in animal models of SBS (Bartholome et al., 2004; Tappenden et al., 1998), its 
volatile nature and lack of commercial availability in parenteral formulas limit its feasibility in 
practice. Fortunately, oral supplementation of prebiotics and probiotics represents a means to 
modulate the intestinal microbiota to deliver butyrate to the intestinal lumen. 
Prebiotic short-chain fructooligosaccharides (scFOS) and probiotic Lactobacillus 
rhamnosus GG (LGG) individually convey butyrogenic effects in animals and humans (Canani et 
al., 2015; Paineau et al., 2014). However, the combination of the two has not been tested for 
potential interactions. Furthermore, scFOS is likely to be fully fermented in the intestinal tract 
due to its low degree of polymerization (3-5 units) when compared to other prebiotics such as 
inulin (10-60 units), but due to the altered motility associated with SBS, it is unclear where the 
prebiotic will ultimately be fermented and thus SCFA will be produced. Along the same lines, 
LGG is known to increase total fecal Lactobacillus spp. (Ohashi et al., 2007), but where the 
probiotic might colonize and potentially exert effects has yet to be determined. 
Bacteria in the intestine produce butyrate through two different pathways, with the 
butyryl-CoA:acetate CoA transferase (BCoAT) pathway being predominant (Louis & Flint, 
2009). In vitro studies have demonstrated that BCoAT utilizes exogenous lactate and acetate as 
reactants (Duncan, Louis, & Flint, 2004; Muñoz-Tamayo et al., 2011), implying that bacterial 
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syntrophy leads to a majority of butyrate production in the intestine. While possession of BCoAT 
is considered a definite marker for bacterial capacity to produce butyrate, higher taxonomical 
classification cannot be utilized in a similar manner. For example, only approximately 40% of 
the tested members of the Lachnospiraceae family are known to produce butyrate (Meehan & 
Beiko, 2014). Similarly, species within the same genus may also be discordant for butyrate 
production, highlighting the need for butyrate-producers to be studied at the species level. 
Therefore, this study investigated the effects of scFOS and LGG on ileal and colonic 
butyrate and lactate producing bacterial populations at the species level, the interaction between 
scFOS and LGG on butyrate and lactate producing bacterial populations, and potential 
relationships between microbial populations, their metabolite production, and their modulation of 
intestinal nutrient transport in a neonatal piglet model of SBS. We hypothesized that scFOS 
would increase relative abundance of total butyrate-producers, their metabolic partners, and 
nutrient absorption, LGG would increase relative abundance of total Lactobacillus, and that 
scFOS plus LGG would exert effects of both individual treatments. 
 
2.3 METHODS 
2.3.1 Experimental Design. 
Our neonatal piglet model of SBS has been described previously (Barnes et al., 2012), but in 
brief, neonatal piglets (48 hours old, N = 39) underwent surgery for 80% jejunoileal resection (to 
induce intestinal failure) and jugular catheterization (for delivery of parenteral nutrition, PN). 
Piglets received 80% PN and 20% enteral nutrition (EN) in the form of commercial sow milk 
replacer and 1 of 4 treatments for 7 days:  
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1. Control (CON - 20% unsupplemented EN/80% standard PN; n = 10)  
2. Control plus prebiotic (PRE - 10 g/L scFOS; NutraFlora, GTC Nutrition, West Chester, IL; n 
= 10)  
3. Control plus probiotic (PRO - 109 colony-forming units [CFU] LGG; Culturelle, i-Health, Inc, 
Cromwell, CT; n = 10)  
4. Control plus synbiotic (SYN - 10 g/L scFOS and 109 CFU LGG; n = 9)  
 
2.3.2 Bacterial DNA extraction, amplification, sequencing, and bioinformatics. 
Total DNA was extracted from frozen samples of digesta and of whole mucosal samples 
originating from the distal ileum and proximal colon. Up to 0.5g of each sample (average 0.26g) 
was weighed directly into lysing tubes for the FastDNA® Spin Kit for Feces and the FastPrep® 
Instrument (MP Biomedicals, Santa Ana, CA). Final elution was performed with 60μL TES 
solution, and samples were stored at -20°C before PCR applications.  
Microbial butyryl-CoA:acetate CoA transferase (BCoAT) (Louis & Flint, 2007), acetyl-
CoA synthase (ACS) (Gagen et al., 2010), and β-fructofuranosidase (β-FFase) (Ehrmann, 
Korakli, & Vogel, 2003) DNA were quantified via qPCR. Gene abundance was normalized to 
abundance of 16s rRNA gene so that normalization of functional gene abundance and taxa 
identification via sequencing would have the same inherent biases, considering the primary goal 
was to correlate functional gene abundance to sequencing data to identify species of interest. 
This normalization yielded similar results as normalization to total DNA, but with higher 
statistical resolution between treatments.  
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Bacterial 16s rRNA genes (V3-V5) were PCR amplified from DNA primers 357F with 
the MiSeq adapter sequence and 926R with unique sample barcodes (Jeraldo et al., 2014). 
Quality and quantity of purified amplicons were assessed via gel electrophoresis and Qubit 2.0 
Fluorometer (Life Technologies, Grand Island, New York). An equimolar amount of the 
amplicons were sequenced using Illumina sequencing on a MiSeq using v3 reagents (Illumina 
Inc., San Diego, California) at the W. M. Keck Center for Biotechnology at the University of 
Illinois. Taxonomy assignment and quality control were determined with Illinois-Mayo Tornado 
pipeline (Jeraldo et al., 2014) utilizing the Silva v123 database with a 100% similarity threshold 
for OTU representative picking. Read length was required to be at least 75% of sequence length 
(225bp) for inclusion. Analyses were conducted for main effects (scFOS = PRE, SYN; LGG = 
PRO, SYN) and individual treatments (CON vs PRE vs PRO vs SYN). QIIME v1.9.1 (Lozupone 
& Knight, 2005; Vázquez-Baeza et al., 2013), JMP PRO v12.2.0, SparCC (Friedman & Alm, 
2012), and LEfSe (Segata et al., 2011) were utilized to assess differences in diversity, relative 
taxa abundance, OTU correlation networks, and discriminant analyses respectively. Wilcoxon 
test was utilized when analyzing sequencing count data, whereas ANOVA and posthoc Fisher’s 
least significant difference was utilized for quantitative PCR and SparCC generated data. 
Correlation analysis was conducted by Pearson correlation, except in cases involving sequencing 
data, in which case Spearman correlation was implemented. 
 
2.3.3 Mucosal nutrient and ion transport. 
Nutrient transport through induced ion flux was measured in modified Ussing chambers as 
previously described (Barnes et al., 2012). Correlations with these and microbial sequencing data 
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were conducted by Spearman’s rho. Since this is a rank-based method, testing for potential 
outliers was not necessary. 
 
2.3.4 Butyrate concentration of colonic digesta. 
Concentrations   of   butyrate   were determined using GLC  (Erwin  et  al.,  1961).  Briefly, 
concentrations were determined using a Hewlett-Packard 5890A  Series  II  gas-liquid  
chromatograph (Agilent, Santa Clara, CA) and a glass column (180 cm by 64 mm i.d.) packed 
with 10% SP-1200/1%  H3PO4  on  80/100  mesh  Chromosorb  WAW  (Supelco Inc., 
Bellefonte, PA). Concentrations were then corrected on a dry-matter basis. 
 
2.3.5 Mucosal RNA extraction and quantification. 
Total RNA was isolated from mucosal tissue as previously described (Barnes et al., 2012).  
Mature transcripts for nutrient transporters were quantified utilizing the Fluidigm system for 
quantitative polymerase chain reaction with Evergreen detection (Fluidigm Corp, San Francisco, 
CA). Primers utilized for Peptide Transporter 1 (PepT1) and Sodium-Glucose Cotransporter 1 
(SGLT1), carnitine palmityl-CoA transferase 1α (CPT1a), and peroxisome proliferator-activated 
receptor gamma coactivator 1α (PGC1a) are reported in Table 2.8. Data were analyzed via 
ANOVA with posthoc Fisher’s least significant difference. 
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2.4 RESULTS 
2.4.1 Animal growth and nutrition support. 
Animal weight, weight gain, calorie intake from EN and PN, and organs weights (other than 
spleen) did not differ between groups. These results have been discussed in higher detail 
previously (Barnes et al., 2012). 
 
2.4.2 Sequencing: Total reads and rarefaction. 
Sequencing of the V3-V5 region of the 16s rRNA gene amplicons yielded 33,368,253 total 
paired reads. After quality control, 8,064,690 high-quality sequences (median 41,584.5 
sequences per sample) representing 7 phyla, 119 families, 375 genera, and 1,281 OTUs were 
utilized in analyses. To include as many samples as possible while still controlling for 
sequencing depth, rarefaction was performed to 24,000 sequences per sample, representing 31 
piglets (CON = 8, PRE = 7, PRO = 9, SYN = 7). 
 
2.4.4 scFOS increases diversity in ileal digesta driven by lower abundance taxa. 
Species richness was determined via alpha diversity metrics: chao1, total observed OTUs, and 
whole tree phylogenetic distance. scFOS increased Chao1 alpha diversity in the ileal digesta 
(groups not receiving scFOS versus those which did, median  127.2 ± 42.3 compared to 168.6 ± 
50.5, P = 0.0427) (Figure 2.1, A). scFOS tended to increase total observed OTUs (P = 0.087) 
and whole tree phylogenetic distance (P = 0.063) but did not reach statistical significance. This 
increase in rare taxa was correlated with total butyrate-producing bacteria (TBP) (R2 = 0.598, P < 
0.01) (Figure 2.1, B), establishing a connection between bacterial diversity and butyrate 
production. 
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 The effects of scFOS on lower abundance taxa was further corroborated by UniFrac beta 
diversity analysis of the ileal digesta. Interestingly, subjects within treatment group did not 
cluster when analyses were restricted to all OTUs, or taxa representing ≤ 10% or ≤ 1% relative 
abundance within each subject (data not shown). However, when restricted to OTUs representing 
≤ 5% relative abundance, all treatments clustered (as demonstrated by within group distances) 
except for CON (Figure 2.1, C and D). Furthermore, between-group distances revealed that 
PRE was distinct from all treatments except for SYN, which was distinct from CON but not 
PRO. Principal coordinates 1-3 accounted for 22.97%, 20.13%, and 10.06% of the variation 
respectively. There were no differences in alpha or beta diversity in other segment locations 
(ileal mucosa, colonic digesta, or colonic mucosa; data not shown). 
 
2.4.5 Total Sequences of Butyrate-producers (TBP) is a better predictor of [Butyrate] in the 
colonic digesta than BCoAT. 
Butyrate concentration in the colonic digesta was not different between treatments in the subset 
of subjects for which an appropriate amount of sample was still available (N = 23; CON = 5, 
PRE = 5, PRO = 10, SYN = 3) (Figure 2.2, A). Due to the small amount of residual digesta 
remaining in the segment at the time of euthanasia (indicating that the window of active 
fermentation had already passed with the vast majority of the contents) ileal digesta samples 
were deemed inappropriate for this analysis. 
Initially, community metabolic potential for butyrate production was assessed by BCoAT 
DNA abundance via qPCR.  However, the bias of these primers to exclude known butyrate-
producers (Levine et al., 2013) and inability to incorporate butyrate-producers that do not utilize 
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BCoAT (such as those which utilize butyrate kinase) limits the interpretation of these results, so 
a sequencing-based approach is proposed as follows. 
 OTUs resolved at the species level representing known butyrate-producers (as 
demonstrated by the literature (Eeckhaut et al., 2011; Levine et al., 2013; Louis & Flint, 2009; 
Vital et al., 2014)) were extracted from the sequencing data for each sample, representing a total 
of 26 species to create the metric TBP (Table 2.2). 
 These methodologies were then tested against actual butyrate concentrations correlation 
analysis. BCoAT was not correlated to butyrate concentration (R2 = 0.060, P = 0.801) (Figure 
2.2, B), but TBP was (R2 = 0.611, P = 0.004) (Figure 2.2, C) 
 
2.4.6 scFOS and SYN increase total butyrate-producing bacteria in the ileal digesta, associated 
with increased glucose absorption. 
scFOS increased BCoAT DNA abundance in the ileal digesta as a main effect (P = 0.0073) 
(Figure 2.3, A) as did PRE and SYN versus CON (P = 0.0498) (Figure 2.3, B). SYN had lower 
BCoAT DNA abundance in the ileal mucosa compared to PRE and PRO, but was not different 
from CON (Table 2.1). There was no change in the colon.  
Abundance of TBP was increased by scFOS as a main effect in the ileal digesta (P = 
0.040) (Figure 2.3, C) and by SYN versus CON and PRO (P = 0.0497) (Figure 2.3, D). This 
pattern of total butyrate producer abundance reflected the changes in BCoAT DNA abundance, 
further validating this approach. To investigate if more butyrate-producing bacteria elicited 
functional intestinal adaptation in the ileum, we examined their relationship to active nutrient 
transport. While there were no differences by treatment (Barnes et al., 2012) active ileal glucose 
transport was modestly correlated with total butyrate producer abundance (R2 = 0.477, P = 
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0.0529) (Figure 2.3, E). These results are promising, but limited in that glucose absorption is 
also mediated by facilitated diffusion in the intestine, which is not captured by the Ussing 
chamber technique. 
 Active glucose transport in the small intestine is mediated by sodium-glucose 
cotransporter 1 (SGLT1), so transcription of the gene was investigated for its potential 
involvement in this mechanism. SGLT1 expression did not differ by treatment (P = 0.872) 
(Table 2.8) and was not correlated with active glucose transport (R2 = 0.0824, P = 0.723). There 
were no differences in SGLT1 expression in the colon (P = 0.700). 
 The LGG had variable effects on butyrate producer abundance by segment. LGG 
increased total butyrate producer abundance at the ileal mucosa as a main effect (P = 0.0428) 
and PRO decreased their abundance in both colonic digesta (P = 0.0438) and mucosa (P = 
0.0454) (Table 2.1). 
 
2.4.7 Different butyrate-producers are discriminant for PRE and SYN in the ileal digesta. 
Differences in individual butyrate-producing species were analyzed to investigate potential 
interactions between scFOS and LGG in the ileal digesta. Clostridium lavalense, which was 
below detection in all CON subjects, was increased by PRE but undetectable in all but one 
subject from SYN (P = 0.0477) (Figure 2.4, A). SYN increased abundance of Flavinofractor 
plautii, Faecalibacterium prausnitzii, and Anaerotruncus colihominis (P = 0.0492, 0.0474, and 
0.0540 respectively) (Figure 2.4, B, C, and D). 
 LEfSe analysis discovered different butyrate-producers as well as taxa known to utilize 
butyrate were discriminant for all treatments except for CON (Figure 2.4, E). While increased 
Lachnospiraceae abundance was the most discriminant taxa to arise from this analysis and was 
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representative of PRE, this may or may not reflect a difference in butyrate production since only 
approximately 40% of its members are known to produce butyrate. Butyrate utilizers 
Pseudomonas and Brevundimonas vesivularis were also discriminant for PRE. The only 
butyrate-related taxa discriminant for PRO was the utilizer Massilia. Interestingly, 
Flavinofractor plautii was discriminant for SYN along with the butyrate-utilizing genus 
Lachnoclostridium. 
 
2.4.8 LGG increases total Lactobacillus with negative effects on ileal peptide absorption. 
As one of the major lactate producing genera in the intestine, Lactobacillus was investigated for 
its potential contribution of lactate for butyrate production. 17 Lactobacillus spp. were resolved 
at the species level for analyses (Table 2.2). Lactobacillus rhamnosus (the probiotic) was 
represented by a single OTU, which was only detectable in PRO and SYN, mostly accumulating 
in the ileal digesta (Figure 2.5, A). LGG supplementation resulted in an increase in total 
Lactobacillus in the ileal digesta (P = 0.0415) (Figure 2.5, B) and ileal mucosa (P = 0.0043) 
(Figure 2.5, C) which was highest at the ileal mucosa with SYN (P = 0.0387) (Figure 2.5, D) 
and distinguished by a marked increase in L. ruteri, which was only detectable in one subject not 
receiving LGG (P = 0.0045) (Figure 2.5, E). Lactobacillus abundance was not changed in the 
colon (Table 2.3). 
 In vitro assays have demonstrated different preferences of D- versus L- isoforms of 
lactate by butyrate-producing taxa(Su et al., 2013). Furthermore, infants with SBS are at high 
risk for D-lactic acidosis, due to high microbial lactate production and minimal ability to 
metabolize D-lactate at an appreciable rate (Kowlgi & Chhabra, 2015). Hence, OTUs 
representing Lactobacillus spp. were parsed by production of D-, L-, or mixed DL-lactate 
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(Connolly, Felis & Dellaglio, 2007; Morita et al., 2010). PRO tended to increase the abundance 
of solely D-lactate producing Lactobacillus in the ileal digesta (P = 0.0712) (Figure 2.5, F), 
which was negatively correlated with ileal Gly-Sar (dipeptide) transport (R2 = -0.485, P = 
0.0567) (Figure 2.5, G). 
 Dipeptide transport in the small intestine is mediated by peptide transporter 1 (PepT1), so 
transcription of the gene was investigated for its potential involvement in this mechanism. PepT1 
expression did not differ between treatments (P = 0.981) (Table 2.8) but was moderately 
correlated with dipeptide transport (R2 = 0.472, P = 0.0357). There were no differences in PepT1 
expression in the colon (P = 0.926). 
 Specific Lactobacillus spp. were negatively correlated to BCoAT DNA abundance and 
total butyrate-producers in the ileal digesta in PRE and PRO groups, but notably these 
relationships were flipped to positive correlations in SYN (Table 2.4). 
 
2.4.9 ACS DNA Abundance. 
Community metabolic potential for acetate production was assessed by ACS DNA abundance 
via qPCR. There were no differences in ACS DNA abundance by treatment in neither ileum nor 
colon (data not shown). 
 
2.4.10 Abundance of specific Bacteroides species is differentially altered by treatment. 
Bacteroides and Lactobacillus are implicated in the digestion of scFOS and related prebiotics 
due to their production of β-Fructofuranosidases (β-FFase) (Goh & Klaenhammer, 2015). 
Relative abundance of Bacteroides did not differ by treatment in any intestinal segment (data not 
shown) but many differences were present at the species level. In short, scFOS, PRE, and SYN 
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increased abundance of specific Bacteroides spp. in the ileal digesta while LGG and PRO 
decreased abundance of specific Bacteroides spp. in the colonic digesta and mucosa (Table 2.5). 
 
2.4.11 Abundance of β-Fructofuranosidases is correlated to Lactobacillus spp., Bacteroides 
spp., and butyrate-producing species. 
Community potential for β-FFase production was assessed by qPCR amplification of the core 
region of known β-FFase genes (Ehrmann et al., 2003). There were no differences between 
treatments in β-FFase DNA abundance in any intestinal segment (data not shown), but across all 
samples β-FFase was correlated to relative abundance of several species of interest: 
Lactobacillus rhamnosus (R2 = 0.486, P < 0.01) and L. equicursoris (R2 = 0.335, P = 0.034), 
Bacteroides thetaiotaomicron (R2 = 0.522, P < 0.01) and B. faecis (R2 = 0.375, P = 0.018), and 
butyrate-producers Eubacterium limosum (R2 = 0.508, P < 0.01) and Anaerotruncus colihominis 
(R2 = 0.414, P < 0.01) (Table 2.6). 
 
2.4.12 Treatments create unique, specialized niches for butyrate-producers in the ileal digesta. 
To further explore the relationships between relative abundances of members of the butyrate-
producing microbial community, SparCC network analysis was conducted on all OTUs in the 
ileal digesta. Networks for butyrate-producers of interest (Clostridium lavalense, Flavinofractor 
plautii, Faecalibacterium prasusnitzii, Anaerotruncus colihominis, and Eubacterium limosum) 
were examined in greater detail by selecting for relationships with their first-degree neighbors, as 
exemplified by the network of F. plautii  (Figure 2.6, A). Interestingly, no first-degree 
relationships were shared across treatment groups within each of these five organisms. Network 
analysis metrics were calculated to examine entire networks of all 26 butyrate-producing species, 
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consistently revealing across all metrics that all treatments decreased centrality and connectivity 
of butyrate-producers compared to CON (Table 2.7).  However, these changes are not likely due 
to decreased relative abundance of butyrate-producers, as demonstrated in Figures 2.3 and 2.4. 
Interestingly, Lactobacillus spp. and Bacteroides spp. both mimicked the same changes of 
decreased centrality and connectivity as butyrate-producers (Table 2.7). Furthermore, network 
parameter degree (number of abundance correlations) of butyrate-producers was decreased by 
PRE, PRO, and SYN vs CON (P < 0.0001). However, this decrease was due to a decreased 
number of negative degree (negative correlations) and increased number of positive degree 
(positive correlations); CON had a higher negative degree compared to all other treatments (P = 
0.0074) (Figure 2.6, C); PRE had a higher positive degree compared to all other treatments (P < 
0.0001) while PRO and SYN also had a higher positive degree than CON (Figure 2.6, B).  
 
2.4.13 Mitochondrial fatty acid import and biogenesis are regulated oppositely in the ileum by 
scFOS supplementation 
In order to support the idea that increased abundance of TBP is associated with a higher 
production of butyrate, expression of mitochondrial genes were examined. Intestinal 
mitochondrial fatty acid importer CPT1a (Vanhoutvin et al., 2009) is up-regulated by colonic 
butyrate enemas at physiological concentrations in healthy, adult humans, and PGC1a (involved 
in mitochondrial biogenesis (Austin & St-Pierre, 2012)) is up-regulated in skeletal muscle and 
brown adipose of C57BL/6 mice consuming a high-fat diet supplemented with butyrate (Gao et 
al., 2009) (Figure 2.7). 
 Interestingly, PGC1a was increased in the ileum by PRE vs CON and PRO (P = 0.0359) 
and by pooled means for treatments including scFOS vs those that did not (P = 0.0057); while 
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CPT1a tended to be decreased by PRE vs CON and PRO (P = 0.0736) and by pooled means for 
treatments including scFOS vs those that did not (P = 0.0589). There were no treatment effects 
on either CPT1a or PGC1a in the colon (P = 0.9187 and 0.4930). 
 
2.5 DISCUSSION 
 The objective of this study was to determine the effects of scFOS and LGG -as well as 
their interactions- on the butyrate-producing microbial community and its relationships to 
nutrient absorption in a neonatal piglet model of SBS. While numerous studies have examined 
the effects of synbiotic treatments, none to our knowledge have looked at the effects of the 
prebiotic and probiotic individually in a side-by-side comparison with their synbiotic 
combination. Our data demonstrate that a synbiotic treatment should not be assumed to simply 
convey an additive or blended effect of both pre- or probiotic alone.  In some cases the synbiotic 
did resemble a blend of both scFOS and LGG (as with diversity and abundance of total butyrate-
producers and Lactobacillus) but when examined at the species and OTU level, the synbiotic 
acted uniquely. Whether this interaction would hold true in individuals without altered intestinal 
physiology or disease is undetermined. 
 Our study was limited by the utilization of a single time point, which may or may not 
reflect changes in intestinal physiology and microbial populations with more acute or chronic 
administration. The 7-day time point was utilized to coincide with the appearance of robust 
markers of structural and functional adaptation in these piglets. The strengths of this study 
include: examination of microbial communities of both the mucosa and digesta in both the ileum 
and colon, the use of sequencing methodology that enabled us to resolve taxonomy at the species 
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level, and application of a comprehensive approach to assessing changes in the butyrate-
producing community which includes their metabolic partners. 
 Butyrate production is often assessed by fecal concentration, but this method may not be 
adequate. The low degree of polymerization of scFOS allows for rapid bacterial digestion and 
fermentation of the prebiotic. Therefore, no scFOS may reach the colon – traditionally 
considered the primary site of microbial fiber fermentation – or the point of excretion due to 
microbial metabolism and rapid intestinal absorption of the metabolites. Our data indicates that 
the primary site of scFOS fermentation is the ileum, as indicated by increases in diversity, 
species expressing β-FFase, butyrate-producers, and shifts in microbial networks, and expression 
of PGC1a. Since butyrate and lactate production is central to energy metabolism of these 
organisms and ATP synthesis is directly linked to microbial biomass (Sorokin & Kadota, 1972), 
it is reasonable to assume that higher abundance of these organisms would be associated with 
higher metabolite production. 
 As mentioned, digestion of scFOS requires microbial β-FFase, primarily produced by 
Lactobacillus, Bifidobactrium, and Bacteroides in the intestine (Comstock, 2009; Falony et al., 
2009; Goh & Klaenhammer, 2015; Van Meulen et al., 2006). The absence or extremely low 
abundance of Bifidobacteria in pigs (Brown et al., 1997; Hartemink & Rombouts, 1999; 
Mikkelsen et al., 2003) and complete absence of Bifidobacteria in our sequencing data simplified 
our analysis. The high abundance of Bacteroides in the intestine implies that they might 
normally be the primary digesters of scFOS in piglets. Specific Bacteroides species known to 
possess β-FFase (notably B. thetaiotaomicron) were increased by scFOS supplementation but 
decreased by LGG. The increase in total Lactobacillus with LGG supplementation may lead to 
Lactobacillus assuming a greater portion of scFOS digestion in SYN. This is potentially 
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problematic since Lactobacillus spp. tend to possess either membrane anchored or intracellular 
β-FFases (Goh & Klaenhammer, 2015), leading to internal digestion and sequestering of scFOS; 
whereas Bacteroides spp. tend to express secreted β-FFases which would lead to external 
digestion of scFOS and higher monosaccharide and other metabolite availability to the microbial 
community as a whole (Falony et al., 2009). Investigation of the forms of β-FFase expressed by 
our species of interest is required to reach a definite conclusion. 
 The intestinal microbiota is known to modulate nutrient availability and absorption in the 
distal intestine (Krajmalnik-Brown, et al., 2012; Scholz-Ahrens et al., 2007). While there were 
no treatment effects on ileal active glucose or peptide transport, we did observe relationships 
between nutrient transport and abundance of specific microbial communities. Stimulation of 
enteroendocrine L-cells with butyrate in cell culture and murine models results in secretion of 
glucagon-like peptide 2 (Kuhre et al., 2016; Tolhurst et al., 2012), which in turn modulates 
SGLT1 activity (Cheeseman, 1997). Similarly, we demonstrated that increased abundance of 
butyrate-producing bacteria is associated with increased active glucose transport without a 
change in mRNA expression (which was also not related to transporter activity). The relationship 
between abundance of D-lactate producing Lactobacillus and ileal peptide transport is more 
complicated. The limited ability of the intestine to metabolize D-lactate combined with high 
lactate production due to an increase in total Lactobacillus may overcome the threshold of the 
intestine (Kowlgi & Chhabra, 2015) and other microbes (Hashizume et al., 2003) to handle 
organic acids in a timely manner, leading to a change in enterocyte to lumen pH gradient. Cell 
culture study of the effects of pH gradient on PepT1 indicates that the transporter has a single 
proton binding site symmetrically available intra- and extracellularly, which assumes an inward 
and occluded state during altered pH gradients, thus disrupting normal peptide transport 
	 49 
(Nussberger et al., 1997). This evidence is especially impactful, as several probiotic 
Lactobacillus spp. (including LGG) are marketed towards and utilized in infants specifically 
because the probiotic itself produces only L-lactate. Our data demonstrate that L-lactate 
producing LGG can cause an increase in D-lactate producing species (rebutting this logic) with 
potential negative impact on peptide absorption in our model. Alternatively, the activity of both 
SGLT1 (Arthur et al., 2014) and PepT1 (Daniel & Stelzl, 2016) are regulated by direct 
glycosylation, which may or may not be altered by microbial activity. 
 Our microbial network analysis indicated that treatments lead to lower direct involvement 
of butyrate-producers in the overall bacterial community. This may be perceived to conflict with 
our association of butyrate-producers with increased diversity. However, decreased network 
centrality may reflect that the supplementation of new resources (e.g. by scFOS and LGG) may 
liberate butyrate-producing bacteria from scavenging a multitude of resources from many other 
taxa and foster more positive, stronger relationships with specific members of the community. 
The lack of overlap between first-degree neighbors of our butyrate-producing species of interest 
supports the idea that our synbiotic combination is different than both prebiotic and probiotic 
alone. 
 Overall, our study further demonstrates the superiority of prebiotic scFOS in stimulating 
butyrate production and thus functional intestinal adaptation over probiotic LGG, which may 
actually induce some detriment in a piglet model of SBS. A more suitable probiotic to combine 
with scFOS to maximize butyrate production and intestinal adaptation requires study. 
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2.6 FIGURES AND TABLES 
  
Figure 2.1  scFOS increases bacterial diversity that is associated with increased butyrate-producing bacteria in the ileal 
digesta. As a main effect, scFOS increases chao1 alpha diversity (A), which is correlated to total butyrate producers (B). 
Box plots represent the minimum and maximum values, interquartile range, and median. Significant difference was 
determined by Wilcoxon rank-sum; correlation is calculated by Spearman’s rho. Weighted UniFrac beta diversity 
distances for CON, PRE, PRO, and SYN groups were differentiated when only operational taxonomic units representing 
≤ 5% of each sample were retained (C, D). Each point represents all microbial sequences retained in a given sample with 
98% confidence intervals for position represented by the halo effect. Within group distances indicate that all treatments 
created a more selective environment than CON, and that populations in PRE and SYN were distinct from CON; PRE 
was distinct from PRO.
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Figure 2.3  scFOS and Synbiotic increase total butyrate producers in the ileal digesta, which is associated with ileal active 
glucose transport. BCoAT is increased by scFOS (A), PRE, and SYN (B). Consistently, total butyrate producing bacteria 
as quantified by sequencing data is also increased by scFOS (C) and SYN (D). In a subgroup for which both Ussing and 
sequencing data was available, total butyrate producers was correlated to ileal glucose absorption as measured by ion flux 
in modified Ussing chambers (E), demonstrating the relationship between butyrate production and functional intestinal 
adaptation. Significant difference was determined by ANOVA with post-hoc Fisher’s LSD (BCoAT) or Wilcoxon rank-
sum (total butyrate producers); correlation is calculated by Spearman’s rho. A,B,C different letters between treatments 
represents a significant difference.
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Figure 2.4  Different butyrate producers are discriminant of Prebiotic and Synbiotic in the ileal digesta. As 
determined by sequencing data, Clostridium lavalense (A) was increased by PRE, while Flavinofractor plautii (B), 
Faecalibacterium prausnitzii (C), and Anaerotruncus colihominis (D) were increased by SYN. Significant 
difference was determined by Wilcoxon rank-sum; boxes without a common letter differ. LEfSe analysis (E) 
demonstrates that contrasting butyrate producers – Lachnospiraceae family in PRE, Flavonifractor plautii and 
Lachnoclostridium genus in SYN – and known butyrate utilizers – Pseudomonas genus and Brevundimonas 
vesicularis in PRE, Massilla genus in PRO- serve to discriminate between each treatment.
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Figure 2.5  LGG increases total Lactobacillus with potential negative impact on peptide absorption in ileum. 
Lactobacillus rhamnosus – the probiotic – was represented by a single OTU that was present in only PRO and SYN, 
mostly accumulating in the ileal digesta (A). Total Lactobacillus spp. was increased in the ileal digesta (B) and 
mucosa (C) by LGG as well as mucosa by SYN (D). Increase in total Lactobacillus by LGG on the mucosa was 
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Ussing chambers (G). Significant difference was determined by Wilcoxon rank-sum. Correlation is calculated by 
Spearman’s rho. A,B,C different letters between treatments represents a significant difference.
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Figure 2.6  All treatments create unique, specialized niches for butyrate producers in the ileal digesta. SparCC 
correlation network analysis was performed for all OTUs within each treatment; the networks of Flavonifractor 
plautii and its first degree neighbors are shown (A). F. plautii is represented by the yellow, circular node, other 
OTUs as blue, rectangular nodes, and their corresponding correlation coefficients as the green (positive) and red 
(negative) edges. Edges are longer for greater negative magnitude and shorter for greater positive magnitude. 
Network parameter degree (number of abundance correlations) of butyrate producers was decreased by PRE, PRO, 
and SYN vs CON (P < 0.0001). However, this decrease was likely due to a decreased number of negative degree 
(negative correlations, B) and increased number of positive degree (positive correlations, C). Significant difference 
was determined by ANOVA with post-hoc Fisher’s LSD. A,B,C different letters between treatments represents a 
significant difference.
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Figure 2.7 Transcription of mitochondria-related genes in the distal ileum (left) and proximal colon (right).. Bars 
represent the mean of each treatment group ± SEM; CON, PRE, PRO n = 10, SYN n = 9. P values are shown for 
ANOVA across treatments; A,B,C different letters between treatment means represents a significant difference with 
LSD. PGC1a = Peroxisome proliferator-activated receptor gamma coactivator 1 alpha (A); CPT1a = Carnitine 
palmityl-CoA transferase 1 alpha (B).
Ileum Colon 
B 
A 
B 
AB 
0 
0.4 
0.8 
1.2 
1.6 
PG
C
1a
 m
R
N
A
:R
PL
P0
 m
R
N
A 
 
0 
0.4 
0.8 
1.2 
1.6 
PG
C
1a
 m
R
N
A
:R
PL
P0
 m
R
N
A 
 
A 
B 
A 
AB 
0 
0.4 
0.8 
1.2 
1.6 
2 
C
PT
1a
 m
R
N
A
:R
PL
P0
 m
R
N
A 
 
0 
0.4 
0.8 
1.2 
1.6 
2 
C
PT
1a
 m
R
N
A
:R
PL
P0
 m
R
N
A 
 
CON PRE PRO SYN 
P = 0.036 
CON PRE PRO SYN 
P = 0.493 
CON PRE PRO SYN CON PRE PRO SYN 
P = 0.074 P = 0.919 
A 
B 
	 57 
  
Ta
bl
e 
2.
1.
 C
ha
ng
es
 in
 B
ut
yr
at
e 
P
ro
du
ci
ng
 B
ac
te
ria
 b
y 
M
et
ho
d,
 S
eg
m
en
t, 
Lo
ca
tio
n,
 a
nd
 T
re
at
m
en
t. 
U
ni
ts
 fo
r t
ot
al
 
bu
ty
ra
te
-p
ro
du
ce
rs
 (T
B
P
) a
re
 n
um
be
r o
f s
eq
ue
nc
es
 p
er
 2
4,
00
0,
 p
re
se
nt
ed
 a
s 
m
ed
ia
n 
an
d 
IQ
R
. U
ni
ts
 fo
r b
ut
yr
yl
-
C
oA
:a
ce
ta
te
-C
oA
 tr
an
sf
er
as
e 
(B
C
oA
T)
 a
re
 a
rb
itr
ar
y 
qP
C
R
 u
ni
ts
 n
or
m
al
iz
ed
 to
 1
6s
 rR
N
A
, p
re
se
nt
ed
 a
s 
gr
ou
p 
m
ea
ns
 
± 
st
an
da
rd
 e
rr
or
 o
f t
he
 m
ea
n.
 P
 v
al
ue
s 
ar
e 
th
e 
re
su
lt 
of
 W
ilc
ox
on
 ra
nk
-s
um
 (T
B
P
) a
nd
 A
N
O
V
A
 (B
C
oA
T)
. G
ro
up
s 
no
t 
re
pr
es
en
te
d 
in
 th
e 
E
ffe
ct
 c
ol
um
n 
w
er
e 
no
t d
iff
er
en
t b
et
w
ee
n 
on
e-
an
ot
he
r. 
	 
Se
gm
en
t 
Lo
ca
tio
n 
sc
FO
S 
N
o 
sc
FO
S 
LG
G
 
N
o 
LG
G
 
C
on
tr
ol
 
Pr
eb
io
tic
 
Pr
ob
io
tic
 
Sy
nb
io
tic
 
Ef
fe
ct
* 
P 
va
lu
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Butyrate Producers 
Ile
um
 
D
ig
es
ta
 
27
7 
(1
71
.2
5 
- 
53
0)
 
10
4.
5 
(2
4.
5 
- 
37
7.
75
) 
15
9 
(7
2.
25
 - 
46
1.
25
) 
24
7 
(6
3 
- 
54
0.
75
) 
25
3 
(3
3.
5 
- 
48
3.
75
) 
24
7 
(2
76
.5
 - 
87
6.
5)
 
88
 
(7
 - 
15
2.
5)
 
38
3 
(1
62
 - 
47
8.
5)
 
sc
FO
S
 >
 n
o 
sc
FO
S
 
 
S
Y
N
 >
 C
O
N
 
; P
R
E
,S
Y
N
 
> 
P
R
O
 
0.
04
04
 
 
0.
04
97
 
M
uc
os
a 
13
3.
5 
(6
0.
5 
- 
48
0.
25
) 
93
.5
 
(3
5.
75
 - 
22
8.
5)
 
17
2.
5 
(9
0.
75
 - 
50
5.
75
) 
66
 
(3
2 
- 5
40
.5
) 
54
.5
 
(1
7.
5 
- 
18
9.
75
) 
79
 
(4
4 
- 
24
7.
75
) 
13
5 
(8
8 
- 4
45
.5
) 
20
6 
(1
12
.7
5 
- 
88
8.
25
) 
LG
G
 >
 n
o 
LG
G
 
0.
04
28
 
 
 
 
 
 
 
 
 
 
 
 
 
C
ol
on
 
D
ig
es
ta
 
97
1 
(3
08
 - 
15
21
) 
69
9 
(3
32
.5
 - 
17
34
.5
) 
58
2.
5 
(2
20
 - 
11
77
.5
) 
11
20
.5
 
(6
05
.5
 - 
17
52
) 
13
28
 
(6
32
 - 
23
86
.2
5)
 
11
20
.5
 
(4
31
.5
 - 
16
24
.5
) 
58
2.
5 
(1
73
.5
 - 
80
2.
5)
 
76
2 
(2
37
.2
5 
- 
18
56
) 
P
R
O
 <
 
C
O
N
 
0.
04
38
 
M
uc
os
a 
44
3 
(2
38
 - 
98
4.
5)
 
50
1.
5 
(2
91
 - 
83
5.
75
) 
42
9 
(2
67
.5
 - 
93
1.
25
) 
50
9 
(3
26
.7
5 
- 
83
7.
25
) 
69
9 
(5
05
.2
5 
- 
10
93
) 
38
0 
(2
11
 - 
56
5)
 
35
1.
5 
(2
70
.7
5 
- 
73
0.
75
) 
92
0.
5 
(2
45
.5
 - 
15
42
.7
5)
 
P
R
O
 <
 
C
O
N
 
0.
04
54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BCoAT 
Ile
um
 
D
ig
es
ta
 
-1
5.
4 
± 
1.
4 
-2
1.
2 
± 
1.
3 
-1
7.
2 
± 
1.
8 
-2
0.
1 
± 
1.
3 
-2
2.
8 
± 
1.
2 
-1
6.
4 
± 
1.
9 
-1
9.
3 
± 
2.
5 
-1
4.
2 
± 
2.
2 
sc
FO
S
 >
 n
o 
sc
FO
S
 
 
S
Y
N
,P
R
E
 >
 
C
O
N
 
0.
00
73
 
 
0.
04
98
 
M
uc
os
a 
-2
0.
1 
± 
1.
3 
-1
9.
3 
± 
1.
0 
-1
9.
5 
± 
1.
3 
-1
9.
8 
± 
1.
0 
-2
1.
1 
± 
1.
7 
-1
7.
8 
± 
1.
8 
-1
7.
8 
± 
1.
1 
-2
2.
7 
± 
1.
3 
S
Y
N
 <
 
P
R
E
,P
R
O
 
0.
03
89
 
 
 
 
 
 
 
 
 
 
 
 
 
C
ol
on
 
D
ig
es
ta
 
-2
3.
4 
± 
1.
5 
-2
2.
7 
± 
1.
0 
-2
3.
6 
± 
1.
1 
-2
2.
5 
± 
1.
3 
-2
3.
4 
± 
1.
4 
-2
1.
6 
± 
2.
4 
-2
1.
9 
± 
1.
5 
-2
5.
3 
± 
1.
5 
N
on
e 
N
S
 
M
uc
os
a 
-2
3.
2 
± 
5.
7 
-2
3.
7 
± 
1.
0 
-2
4.
3 
± 
1.
5 
-2
2.
6 
± 
1.
3 
-2
2.
4 
± 
1.
6 
-2
2.
7 
± 
2.
0 
-2
4.
7 
± 
1.
3 
-2
3.
7 
± 
2.
5 
N
on
e 
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 58 
  
Table 2.2. Butyrate producing bacterial species and Lactobacillus spp. representative of 
OTUs for utilization in analyses. 
 
Butyrate Producers 
  
Lactobacillus spp. 
Acidaminococcus fermentans 
 
L. acidophilus 
Allistipes shahii 
  
L. agilis 
Anaerofustis sterocorihominis 
 
L. crispatus 
Anaerostipes caccae 
  
L. equicursoris 
Anaerotruncus colihominis 
 
L. G24 
Anaerotruncus NML_070203 
 
L. helviticus 
Butyricicoccus pullicaecorum 
 
L. ii1369 
Butyricimonas OUH_334697 
 
L. JCM8659 
Butyrivibrio uncultured rumen bacterium L. jensenii 
Christensenella minuta 
  
L. johnsonii 
Clostridium butyricum 
  
L. KC45a 
Clostridium lavalense 
  
L. mucosae 
Clostridium symbiosum 
  
L. oral clone HT002 
Coprococcus HPP0048 
  
L. reuteri 
Coprococcus HPP0074 
  
L. rhamnosus 
Eubacterium limosum 
  
L. salivarius 
Eubacterium ventriosum 
  
L. tetragenococcus_halophilus 
Faecalibacterium prausnitzii 
 
Klebsiella pneumoniae* 
Flavonifractor plautii 
   Fusbacterium CSL-7530 
   Fusbacterium varium 
   Fusobacterium nucleatum 
  Megasphaera elsedenii 
   Roseburia hominis 
   Subdoligranulum 54A2FAA 
  Subdoligranulum ic1395 
   
*Implicated in cases of D-lactic acidosis in short-bowel syndrome and only accounted 
 for in D-Lactate producing species calculations 
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Table 2.4. Bacterial species abundanced correlated to community abundance of genomic 
Butyryl-CoA:Acetate CoA Transferase and Total Butyrate Producers in ileal digesta. 
	
 Butyryl-CoA:Acete CoA Transferase  Total Butyrate Producers 
Functional 
Group Organisms by Treatment 
Spearman's 
rho 
P 
value 
 Organisms by Treatment Spearman's rho 
P 
value 
          
B
ut
yr
at
e 
Pr
od
uc
er
s 
PRE None - NS  PRE Clostridium symbiosum 0.872 0.09 
         
PRO 
Clostridium symbiosum 0.733 0.02  
PRO 
Clostridium symbiosum 0.800 0.03 
Butyricicoccus 
pullicaecorum 0.802 0.09  
Butyricicoccus 
pullicaecorum 0.757 0.10 
Flavinofractor plautii 0.655 0.09  
            
SYN 
 
Anaerotruncus 
colihominis 0.963 < 0.01  
SYN 
 
Coprococcus sp. 
HPP0074 0.778 0.05 
Faecalibacterium 
prausnitzii 0.844 0.04     
Eubacterium limosum 0.764 0.05     
Megasphaera elsdenii 0.711 0.07                  
La
ct
ob
ac
ill
us
 
PRE 
Lactobacillus johnsonii -0.872 0.07  PRE 
None - NS 
Lactobacillus reuteri -0.900 0.09     
         
PRO 
Lactobacillus johnsonii -0.889 0.01  
PRO 
Lactobacillus johnsonii -0.927 0.01 
Lactobacillus reuteri -0.865 0.02  Lactobacillus mucosae -0.857 0.01 
Lactobacillus mucosae -0.750 0.07  Lactobacillus reuteri -0.721 0.08 
Lactobacillus helveticus -0.649 0.09  
   Lactobacillus crispatus -0.757 0.10     
Lactobacillus 
rhamnosus -0.606 0.10     
         
SYN 
 
Lactobacillus johnsonii 0.881 0.01  
SYN 
 
Lactobacillus reuteri 0.883 0.01 
Lactobacillus salivarius 0.775 0.07  
Lactobacillus 
equicursoris 0.714 0.09 
Lactobacillus 
equicursoris 0.685 0.09  
Lactobacillus 
rhamnosus 0.667 0.10 
Lactobacillus mucosae 0.618 0.10                  
B
ac
te
ro
id
es
 
PRE 
Bacteroides fragilis 0.9 0.1  
PRE 
Bacteroides stercoris 0.872 0.09 
    Bacteroides uniformis -0.872 0.10 
    Bacteroides caccae 0.894 0.10 
         
PRO 
Bacteroides stercoris 0.775 0.01  
PRO 
Bacteroides vulgatus 0.811 0.03 
Bacteroides 
thetaiotaomicron 0.883 0.01  
Bacteroides 
thetaiotaomicron 0.667 0.10 
Bacteroides vulgatus 0.757 0.05  
Bacteroides 
xylanisolvens 0.722 0.10 
Bacteroides 
xylanisolvens 0.866 0.05  
   Bacteroides uniformis 0.821 0.06   
            
SYN 
 
None - NS  
SYN 
 
Bacteroides stercoris 0.75 0.06 
    
Bacteroides 
xylanisolvens 0.692 0.10 
       Bacteroides vulgatus 0.643 0.10 
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Table 2.6. Bacterial species abundances correlated to community abundance of genomic β-
Fructofuranosidase by Spearman correlation. 
 
Taxonomy Spearman's rho P value 
Lactobacillus   
rhamnosus 0.486 0.0013 
equicursoris 0.335 0.034 
Bacteroides   
thetaiotaomicron 0.522 0.0005 
faecis 0.375 0.018 
Butyrate-Producers   
Eubacterium limosum 0.5076 0.001 
 Anaerotruncus colihominis 0.4144 0.0087 
 
	 63 
  
       Table 2.7. SparCC OTU Network parameters by functional group and treatment. 
	
Functional 
Group 
Network 
Parameter Treatment 
Value 
(Mean, SE) Effect 
P value 
(ANOVA) 
      
Butyrate 
Producers 
Characteristic 
Path 
CON 2.776 ± 0.043 
PRE,PRO,SYN   
> CON < 0.0001 
PRE 3.017 ± 0.035 
PRO 3.040 ± 0.033 
SYN 3.013 ± 0.034 
     
Degree 
CON 24.00 ± 2.339 
CON > 
PRE,PRO,SYN < 0.0001 
PRE 15.00 ± 1.129 
PRO 13.25 ± 1.052 
SYN 13.35 ± 1.233 
     
Positve Degree 
CON 9.065 ± 0.8512 
PRE > 
PRO,SYN 
> CON 
< 0.001 PRE 15.52 ± 1.207 PRO 13.03 ± 0.7985 
SYN 13.06 ± 0.7814 
     
Negative 
Degree 
CON 11.32 ± 1.841 
CON > 
PRE,PRO,SYN 0.0074 
PRE 7.645  ± 0.6729 
PRO 6.742 ± 0.4751 
SYN 6.936 ± 0.5640 
     
Betweenness 
Centrality 
CON 0.001919 ± 0.00027 
CON > SYN 0.0654 PRE 0.001739 ± 0.00024 PRO 0.001498 ± 0.00024 
SYN 0.001253 ± 0.00024 
     
Neighborhood 
Connectivity 
CON 23.85 ± 1.360 
CON > 
PRE,PRO,SYN < 0.0001 
PRE 15.66 ± 0.5078 
PRO 15.90 ± 0.4213 
SYN 16.78 ± 0.5457 
     
Clustering 
Coefficient 
CON 0.05881 ± 0.00822 
No Effect 0.3258 PRE 0.05187 ± 0.00773 PRO 0.03709 ± 0.00749 
SYN 0.04211 ± 0.00739 
     
Closeness 
Centrality 
CON 0.3628 ± 0.00534 
CON > 
PRE,PRO,SYN < 0.0001 
PRE 0.3324 ± 0.00365 
PRO 0.3298 ± 0.00353 
SYN 0.3326 ± 0.00374 
      
Lactobacillus 
Characteristic 
Path 
CON 2.759 ± 0.03934 PRE,PRO,SYN   
> CON 
 
PRO > SYN 
< 0.0001 PRE 2.988 ± 0.03587 PRO 3.018 ± 0.02984 
SYN 2.900 ± 0.03706 
     
Degree 
CON 21.71 ± 2.533 
CON > 
PRE,PRO 0.0384 
PRE 15.53 ± 1.508 
PRO 14.24 ± 1.262 
SYN 17.94 ± 2.061 
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Betweenness 
Centrality 
CON 0.001509 ± 0.00020 
No Effect 0.5460 PRE 0.002114 ± 0.00038 PRO 0.001851 ± 0.00034 
SYN 0.002245 ± 0.00054 
     
Neighborhood 
Connectivity 
CON 26.13 ± 1.526 CON > 
PRE,PRO,SYN 
 
SYN > PRO 
< 0.0001 
PRE 15.67 ± 0.3724 
PRO 15.29 ± 0.4645 
SYN 17.97 ± 0.7045 
     
Clustering 
Coefficient 
CON 0.07274 ± 0.01410 
CON > 
PRE,PRO,SYN 0.0221 
PRE 0.03827 ± 0.00633 
PRO 0.03457 ± 0.00815 
SYN 0.04536 ± 0.00649 
     
Closeness 
Centrality 
CON 0.3636 ± 0.00516 CON > 
PRE,PRO,SYN 
 
SYN > PRO 
< 0.0001 PRE 0.3354 ± 0.00405 PRO 0.3319 ± 0.00337 
SYN 0.3457 ± 0.00430 
      
Bacteroides 
Characteristic 
Path 
CON 2.800 ± 0.03100 PRE,PRO,SYN   
> CON 
 
PRO > PRE 
< 0.0001 PRE 2.975 ± 0.01596 PRO 3.044 ± 0.01860 
SYN 3.007 ± 0.02448 
     
Degree 
CON 21.30 ± 1.762 
CON > 
PRE,PRO,SYN < 0.0001 
PRE 15.45 ± 0.6493 
PRO 13.26 ± 0.6332 
SYN 14.04 ± 0.8592 
     
Betweenness 
Centrality 
CON 0.001634 ± 0.00017 
No Effect 0.3387 PRE 0.001900 ± 0.00014 PRO 0.001585 ± 0.00014 
SYN 0.001521 ± 0.00017 
     
Neighborhood 
Connectivity 
CON 24.38 ± 1.045 
CON > 
PRE,PRO,SYN < 0.0001 
PRE 16.06 ± 0.3906 
PRO 15.41 ± 0.3236 
SYN 16.41 ± 0.3439 
     
Clustering 
Coefficient 
CON 0.05428 ± 0.00634 
No Effect 0.1981 PRE 0.04416 ± 0.00629 PRO 0.03646 ± 0.00599 
SYN 0.03820 ± 0.00701 
     
Closeness 
Centrality 
CON 0.3591 ± 0.00388 
CON > 
PRE,PRO,SYN < 0.0001 
PRE 0.3366 ± 0.00180 
PRO 0.3291 ± 0.00199 
SYN 0.3335 ± 0.00265 
      
         Table 2.7 (cont) SparCC OTU Network parameters by functional group and treatment.	
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CHAPTER 3: PREBIOTIC ENHANCEMENT OF INTESTINAL 
ADAPTATION IN PIGLETS WITH SHORT-BOWEL SYNDROME IS 
ASSOCIATED WITH ENTEROENDOCRINE AND MICROBIAL 
MODIFICATIONS 
 
3.1 ABSTRACT 
 Intestinal resection resulting in short-bowel syndrome (SBS) is associated with an 
enteroendocrine cascade beginning with intestinal secretion of glucagon-like peptide-2 (GLP-2), 
an intestinotrophic hormone, stimulating innate intestinal adaptation. Treatments that increase 
luminal production of short-chain fatty acids (SCFA), such as prebiotics and probiotics, could 
further enhance this process through stimulating higher secretion of GLP-2 from enteroendocrine 
L-cells. The purpose of this study was to determine the interactions between the intestinal 
microbiota, intestinal epithelium, and enteroendocrine system related to intestinal adaptation in 
the distal ileum and proximal colon in the same neonatal piglet model of intestinal failure, treated 
with partial enteral nutrition supplemented with short-chain fructooligosaccharides 
(scFOS)[PRE], Lactobacillus rhamnosus GG (LGG)[PRO], or synbiotic combination of the two 
[SYN]. L-cell density, as assessed by immunofluorescence, did not differ between treatments in 
the ileum (P = 0.602) or the colon (P = 0.4319), but L-cell density was higher in the ileum vs the 
colon (P = 0.0003). mRNA expression of primary GLP-2 signaling elements was enhanced by 
PRE in the ileum, such as decreased expression of Dipeptidyl-peptidase-IV (P = 0.0027), while 
mRNA expression of secondary GLP-2 signaling elements was diminished by PRO in the colon, 
such as decreased expression of insulin-like growth factor-1 (IGF-1) (P = 0.05) and IGF-1 
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receptor (P = 0.02). PRE and SYN decreased abundance of bacterial species detrimental to GLP-
2 signaling, including Enterococcus faecalis (P = 0.04) and Escherichia coli E851/71 (P = 0.01). 
This study indicates that scFOS may enhance primary GLP-2 signaling through altered gene 
expression and decreasing abundance of detrimental bacterial species. 
 
3.2 BACKGROUND 
 Short-bowel syndrome (SBS) is a life-threatening condition affecting premature infants 
following intestinal resection, defined by a reduction in intestinal mass below the amount 
required to independently sustain life. This major insult to the intestine is accompanied by a rise 
in circulating active glucagon-like peptide 2 (GLP-2), an intestinotrophic hormone secreted by 
enteroendocrine L-cells that facilitates adaptation in the remaining intestinal tissue. However, 
GLP-2 does not work alone in this process. Knockout studies of insulin-like growth factor 1 
(IGF-1) in mice revealed its essentiality in mediating intestinal growth in response to GLP-2 
(Dubé et al., 2006). Furthermore, the half-life of GLP-2 is a short seven minutes(Burrin et al., 
2002), primarily due to inactivation by dipeptidyl-peptidase-IV (DPP-IV), which is expressed 
locally in the intestine as well as in the liver. 
 The intestinal microbiota play an important role in the stimulation of the enteroendocrine 
system through their production of short-chain fatty acids (SCFA). L-cells, found most 
abundantly in the distal ileum and proximal colon (Eissele et al., 1992; Hansen et al., 2013; Kaji 
et al., 2011), express membrane free fatty acids receptors 2 and 3 (FFAR2, FFAR3), which 
trigger the secretion of GLP-2 (co-secreted with GLP-1) upon exposure to SCFA (Tolhurst et al., 
2012). However, the cellular location of FFAR2 and FFAR3 has not been defined (and hence 
	 68 
whether they sense luminal or absorbed SCFA), raising the importance of SCFA absorption in 
the process of FFAR signaling. 
 While up to 60% of SCFA are absorbed by the intestinal epithelium through passive 
diffusion (Bugaut, 1987), active transport occurs through monocarboxylate transporter 1 (MCT1) 
and sodium-monocarboxylate transporter 1 (SMCT1) (Halestrap & Wilson, 2012). The 
expression of these transporters is modifiable by dietary factors. For example, expression of 
these transporters was positively correlated to increased SCFA concentrations resulting from a 
5% beta-glucan prebiotic diet in pigs (Metzler-Zebeli et al., 2012). 
 To come full circle, L-cell abundance and FFAR expression are also modified by 
prebiotic supplementation. Although the mechanism is not clear, feeding of a 5% 
fructooligosaccharide diet to rats increased density of FFAR2 and GLP-1 positive L-cells in the 
proximal colon (Kaji et al., 2011).  
Supplementation of prebiotic short-chain fructooligosaccharide (scFOS), but not 
probiotic Lactobacillus rhamnosus GG (LGG), in a neonatal piglet model of SBS resulted in 
robust structural adaptations along the crypt-villus axis (Barnes et al., 2012), although the 
mechanism is yet undetermined. The purpose of this study was to determine the interactions 
between the intestinal microbiota, intestinal epithelium, and enteroendocrine system related to 
intestinal adaptation in the distal ileum and proximal colon of the same neonatal piglet model of 
SBS. We hypothesized that increased butyrate production of the microbiota resulting from 
scFOS supplementation would stimulate an enteroendocrine signaling cascade beginning with 
increased expression and secretion of GLP-2 from L-cells through FFAR2 and FFAR3 signaling, 
ending with increased expression and signaling of IGF-1. 
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3.3 METHODS 
3.3.1 Experimental design, bacterial DNA processing, and mucosal RNA processing. 
The neonatal piglet model of SBS, bacterial DNA extraction, amplification, and sequencing, and 
intestinal mucosal RNA extraction and quantification were detailed previously (see chapter 2). 
For quantitative PCR, n = 10 for each treatment, except for SYN n = 9. Expression of all other 
genes was normalized to ribosomal phosphoprotein P0 (RPLP0), a gene that is expressed stably 
across intestinal cells in different states of differentiation (Dydensborg et al., 2006) 
 
3.3.2 Immunoflueorescent visualization and quantification of GLP-2. 
In order to quantify L-cell density and GLP-2, intestinal sections (distal ileum and proximal 
colon of each subject, n = 8 per treatment) were fixed in formalin for less than 24 hours and then 
transferred to 50% ethanol. Each sample was infiltrated with paraffin wax and sectioned to 
approximately 8 μm thickness with a microtome in triplicate onto positively charged microscope 
slides. Sections were deparaffinized and rehydrated in a series of xylene, ethanol, and phosphate-
buffered saline (PBS) baths at room temperature, and antigen retrieval was performed by 
submerging the sections in Antigen Unmasking Solution (Vector Labs, Southfield, MI) in a 
standing water bath at 98°C for 30 minutes, followed by immediate submersion in tap water for 
10 minutes. Slides were quickly dried and tissue was encircled with a hydrophobic PAP pen. 
Blocking and permeabilization were performed for 30 minutes in 5% donkey serum (Abcam, 
Cambridge, MA), 5% signal FX (Life Technologies Corporation, Eugene, OR), and 0.5% 
saponin (Sigma-Aldrich, St. Louis, MO), in PBS. Primary and secondary antibodies were also 
diluted in 5% donkey serum, 5% signal FX, and PBS. Primary antibody incubation with rabbit-
anti-GLP-2 (Phoenix Pharmaceuticals Inc, Burlingame, CA; catalog # H-028-14) was performed 
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overnight at 4°C at a final dilution of 1:250; continuous mixing was achieved on a Belly Dancer 
shaker (Stovall Life Science Inc, Greensboro, NC). Secondary incubation with goat-anti-rabbit 
Alexa fluor 405 conjugate (Life Technologies Corporation, Eugene, OR; catalog # A-31556) was 
performed at room temperature for 1 hour at a final dilution of 1:200, completely covered and 
obscured from light. Finally, nuclei were stained with TO-PRO-3 (Life Technologies 
Corporation, Eugene, OR; catalog # T3605) at a final dilution of 1:1000. Sections were mounted 
with glass coverslips and Prolong Gold (Life Technologies Corporation, Eugene, OR; catalog # 
P36934) and stored in the dark prior to visualization. 
 Visualization was performed on the Zeiss LSM 700 confocal microscope, utilizing three 
separate laser tracks for fluorescence related to: GLP-2 (405), background (488), and nuclei 
(639). Tile scans of 3x5 frames were taken to encompass a total field of approximately 2 mm2. 
The microscope was manually focused on the depth with the highest nucleus stain intensity prior 
to the scan. 
 Quantification of L-cells, GLP-2 related fluorescence, and mucosal area was assessed in 
Fiji (Schindelin et al., 2012). To select suspected L-cells as regions of interest (ROI), each ROI 
was cross-referenced against the background channel (non-specific fluorescence, 488) and the 
average background from the GLP-2 channel (as determined by manual tracing of the entire 
mucosal area captured) was subtracted from each potential L-cell ROI. 
  
3.3.3 Statistics 
Gene expression and immunofluorescence data were analyzed using the ANOVA procedure with 
Fisher’s LSD for post-hoc separation in JMP Pro 12.2.0. 
 
	 71 
3.4 RESULTS 
3.4.1 L-cell density does not differ between treatments, but is higher in the ileum versus the colon 
across all treatments 
As the enteroendocrine L-cell is central to GLP-2 signaling, we investigated the abundance and 
distribution of the cell type via immunofluorescent staining of the distal ileum and proximal 
colon. Furthermore, knowing whether or not to adjust for L-cell density is a vital aspect for 
analysis and interpretation of L-cell associated gene expression data. 
 Representative images of the ileum and colon of each treatment group and analysis data 
are presented in Figure 3.1. L-cell number and density did not differ between treatments in the 
ileum (P = 0.6913 and 0.6020) or the colon (P = 0.3605 and 0.4319). Total GLP-2 associated 
fluorescence and fluorescence per cell did not differ between treatments in the ileum (P = 0.3772 
and 0.4545) or the colon (P = 0.4328 and 0.5910).   
 While there were no differences between treatments, there were segment-dependent 
differences. Consistent with previous reports, L-cell number and density were higher in the distal 
ileum than the proximal colon across treatments (P = 0.0102 and 0.0003). 
 
3.4.2 Transcription of GLP-2 signaling pathway elements is increased by prebiotic treatment in 
the ileum, and impaired by probiotic in the colon. 
To investigate whether our treatments altered expression of GLP-2 signaling and thus 
contributed to intestinal adaptation, we measured relative, mature transcript levels of FFAR2, 
FFAR3, Proglucagon (the transcript including GLP-2, GCG), DPP-IV, GLP-2R, IGF-1, IGF-1R, 
IGF-2, and IGF-2R in the ileal and colonic mucosa (Figure 3.2). 
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 In the ileum, SCFA receptor FFAR2 was increased by SYN versus PRE and PRO (P = 
0.0497), while FFAR3 was unaffected (P = 0.2741). While GCG was unaffected by treatment (P 
= 0.3457), PRE and PRO decreased DPP-IV expression by 48% (P = 0.0027) and PRO 
decreased GLP-2R compared to PRE (P = 0.0441). Downstream targets IGF-1, IGF-1R, IGF-2, 
and IGF-2R was also unaffected by treatment (P = 0.5509, 0.5512, 0.9357, and 0.7799 
respectively). 
In contrast to the ileum, changes in expression in the colon occurred mainly in 
downstream targets rather than primary targets. FFAR2, FFAR3, GCG, and DPP-IV were 
unaffected by treatment (P = 0.1729, 0.4227, 0.6079, and 0.5311 respectively). Consistent with 
the ileum, GLP-2R was decreased by PRO vs CON and PRE (P = 0.0494). Both IGF-1 and IGF-
1R were also decreased by PRO (IGF-1: P = 0.0496 vs CON and SYN; IGF-1R: P = 0.0228 vs 
CON); IGF-1R was also decreased by SYN vs CON. IGF-2 and IGF-2R were unaffected by 
treatment (P = 0.5098 and 0.6719). 
 
3.4.3 Transcription of insulin-like growth factor binding proteins is altered differentially in the 
ileum and colon by treatments 
Insulin-like growth factor binding proteins (IGFBP) inhibit IGF-1 and IGF-2 from activating 
IGF-R through tight binding interactions (Baxter, 2014). Expression of IGFBP2 and 4 is 
displayed in Figure 3.3.  
In the ileum, pooled means of treatments containing scFOS (PRE, SYN) decreased 
IGFBP2 vs those that did not (P = 0.0376). There were no treatment effects on IGFBP3 or 
IGFBP4 in the ileum (P = 0.8517 and 0.4285). 
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 In the colon, PRE and PRO decreased IGFBP2 and IGFBP4 vs CON and SYN (P = 
0.0146 and 0.0036). Consistent with the ileum, no effects were observed for IGFBP3 in the colon 
(P = 0.1804). Whether IGFBP2 and IGFBP4 are acting to inhibit IGF or to store and release IGF 
in the ileum and colon requires further investigation. 
 
3.4.4 Synbiotic increases expression of short-chain fatty acid transporters in both ileum and 
colon. 
To investigate how changes in SCFA absorption might be involved in enteroendocrine signaling, 
mature transcript levels of MCT1 and SMCT1 were measured in the ileal and colonic mucosa 
(Figure 3.4). 
 In both the ileum and the colon, SYN increased MCT1 vs all other treatments (P = 
0.0067 and 0.0267). SMCT1 was also increased by SYN vs all other treatments in the ileum (P = 
0.0154) but was only decreased by PRO vs CON in the colon (P = 0.0508). 
 Comparing the ileum to the colon, the expression level of the two SCFA transporters are 
contrary. While MCT1 is expressed many times higher in the colon (P < 0.0001), SMCT1 is 
higher in the ileum (P < 0.0001). 
 
3.4.5 Peptide YY transcription indicates differential regulation of motility in the ileum vs the 
colon by treatments 
Peptide YY (PYY) is also a secretory hormone of enteroendocrine L-cells, which reduces both 
gastric emptying and motility in the intestine (El-Salhy, MAZZAWI, GUNDERSEN, et al, 
2012). Cholecystokinin (CCK), another enteroendocrine hormone, also delays gastric emptying 
but has also been reported to increase intestinal motility (Al Mushref & Srinivasan, 2012). Since 
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decreased motility would increase the amount of time that the passing digesta would have to 
interact with the epithelium, we investigated the expression of PYY and CCK in the ileal and 
colonic mucosa (Figure 3.5). 
 Conversely, PYY was decreased by PRE and SYN vs CON and PRO in the ileum (P = 
0.0126) but increased by PRE and PRO in the colon (P = 0.0528). There were no effects 
observed for CCK in either ileum or colon (P = 0.9470 and 0.3650). 
 
3.4.6 Endothelial nitric oxide synthase expression is decreased by PRO in the colon 
GLP-2 has been reported to enhance perfusion of the intestine through mediation of vasoactive 
peptides, namely endothelial nitric oxide synthase (eNOS) (Guan et al., 2003), while 
enteroinvasive bacteria have been demonstrated to directly stimulate inducible nitric oxide 
synthase (iNOS) (Witthöft et al., 1998). 
 There were no differences in eNOS expression in the ileum (P = 0.979). However, eNOS 
expression was decreased by PRO vs. CON and SYN in the colon (P = 0.058) (Figure 3.6). 
There were no differences in iNOS expression in either the ileum or the colon (P = 0.465 and 
0.310). 
 
3.4.7 Expression of pro-inflammatory cytokines is increased by PRO in the ileum 
Expression of both interferon gamma (IFNg) and tumor necrosis factor alpha (TNFa) were 
increased in the ileum by PRO (P = 0.048 and 0.053) (Figure 3.7, A and D). There were no 
differences in IFNg or TNFa in the colon (P = 0.747 and 0.994). There were no differences in 
Interleukin-1B or Interleukin-6 in either the ileum (P = 0.345 and 0.762) or the colon (P = 0.610 
and 0.313) (Figure 3.7, B and C). 
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3.4.8 All treatments decrease abundance of microbial species potentially detrimental to GLP-2 
signaling in the ileum 
In addition to the microbial changes previously reported (see previous chapter), changes in 
abundance of two specific microbial species in the ileal digesta potentially impact the GLP-2 
enteroendocrine signaling pathway (Figure 3.8). 
 Enteropathogenic Escherichia coli reduce intestinal epithelial surface area and induce 
diarrhea(Hodges & Gill, 2010; Moon et al., 1983), effectively reducing SCFA sensing and 
absorption. Derived from 16s rRNA sequencing data, abundance of enteropathogenic 
Escherichia coli E851/71 was reduced by PRE and SYN vs CON (P = 0.0122). To reinforce this 
difference, E. coli E851/71 abundance was the only taxonomic group determinant for the CON 
group in our LEfSe analysis across all treatment groups in the ileal digesta (log10 linear 
discriminant analysis score = 2.73, P < 0.05). 
 Enterococcus faecalis has been demonstrated to degrade 100% of GLPs through 
secretion of gelatinase E (gelE) in co-culture with a human GLP-secreting cell line [unpublished 
data – Dr. Robert Britton Lab, Baylor College of Medicine, 2016]. E. faecalis secretes gelE in 
response to quorum sensing to modulate biofilm formation(Galloway-Peña et al., 2011), 
implying that a high abundance of the bacteria with either impaired barrier function and/or 
bacterial translocation could allow for entrance of gelE into intestinal tissue. Again from our 16s 
rRNA sequencing data, abundance of E. faecalis was reduced below the level of detection in all 
PRE and SYN subjects, significantly lower than CON (P = 0.0446). 
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3.5 DISCUSSION 
  Contrary to previous reports, we did not see an increase in L-cell density in the colon (or 
ileum) with scFOS treatment (Kaji et al., 2011). However, key differences exist between the Kaji 
and colleagues 2010 study and ours including: rats vs piglets, adults vs infants, health vs illness, 
degree of fructooligosaccharide polymerization and level of supplementation, and length of 
intervention. The lower degree of polymerization of scFOS lends it to being rapidly fermented in 
the ileum by the intestinal microbiota, reducing the amount of prebiotic ultimately reaching the 
colon. Conversely, the longer chain length of FOS lends more feasibility to primarily colonic 
fermentation. Furthermore, longer duration and quantity of intervention may be required to 
stimulate higher proliferation and differentiation of enteroendocrine stem cells. Overall, the 
higher density of L-cells in the distal ileum makes it a better target for interventions. 
 The increased expression of FFAR2 in the SYN group must be interpreted carefully, as 
L-cells are not the only enteric cell type to express the receptor. FFAR2 is also highly expressed 
in enteric leukocytes, which vastly outnumber enteroendocrine L-cells in the ileum (Nøhr et al., 
2013). In fact, expression of FFAR2 was not associated with L-cell density (R2 = 0.157, P = 
0.399) but was correlated with expression of TNFa (R2 = 0.443, P = 0.016) (Figure 3.9). The 
role of enteric leukocyte invasion and FFAR2 expression requires further study. 
 The remainder of enteroendocrine modulation was observed in a segment-dependent 
fashion in response to treatment. In the ileum, down-regulation of local DPP-IV expression and 
E. faecalis abundance in PRE and PRO might play a pivotal role in enhancing GLP-2 signaling 
through increasing its short half-life. This benefit may have been blunted by decreased 
expression of GLP-2R and increased expression of IGFBP4 in the PRO group, reflected in the 
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minimal benefit to ileal structural adaptation previously reported for these animals(Barnes et al., 
2012). 
 In the colon, GLP-2 secondary messenger signaling through IGF was negatively 
impacted by PRO. Expression of GLP-2R on subepithelial myofibroblasts is a key mediator of 
their subsequent expression and release of IGF-1(Janssen et al., 2013). This may explain the 
concurrent decrease in expression of both GLP-2R and IGF-1 signaling pathway. IGF-2 and 
IGF-2R were unaffected by treatments in both segments, but this does not necessarily rule out its 
potential importance in mediating intestinal adaptation in the neonatal period. 
 The role of microbial SCFA production -particularly butyrate- from scFOS 
supplementation in stimulating enteroendocrine function is not straightforward. While increased 
abundance of butyrate-producing microbes, expression of MCT1 (Cuff et al., 2002), and 
expression of PGC1a (Gao et al., 2009) commonly point towards higher butyrate exposure of the 
ileum, (hence increasing GLP-2 secretion); competition between SCFA transport and sensing, as 
well as the trend of decreased CPT1a are more difficult to account for. Both SCFA receptors and 
transporters followed the same pattern of higher expression in the colon versus the ileum.  
MCT1 expression increases in response to butyrate (but not acetate or propionate) in a 
dose- and time-dependent fashion. SYN may have increased MCT1 expression even when 
compared to PRE due to a rapid fermentation of scFOS due to the addition of LGG (which 
possesses the enzymes to digest scFOS) versus a more even and distributed fermentation profile 
in PRE. 
An increase in PGC1a expression is linked to mitochondrial biogenesis and is increased 
by butyrate, but is usually also linked to CPT1a through Peroxisome proliferator-activated 
receptor alpha (Song et al., 2010). However, CPT1a is highly expressed in the intestine, and a 
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decrease in its overall expression is unlikely to affect mitochondrial β-oxidation due to an 
enrichment of MCT1 in porcine intestinal mitochondria (Welter & Claus, 2008). Whether or not 
changes in MCT1 were due to increased number of mitochondria per cell in these animals is 
unknown. 
PYY may be as good of an indicator of nutrient processing as it is motility in this study. 
PYY is secreted to slow down intestinal transit rate when high concentrations of nutrients reach 
the distal intestine. In our PRE and SYN treatments, robust structural and functional adaptations 
in the small intestine would increase nutrient digestion and absorption, decreasing the need for 
PYY to slow transit, as reflected by its reduced ileal expression in these groups. Increased 
expression of PYY in the colon of PRE and PRO may be a segment-specific adaptation allowing 
the colon to facilitate higher absorptive function following intestinal failure. Local effects of 
PYY expression and secretion require further investigation. 
In summary, microbial fermentation of scFOS is associated with enteroendocrine and 
microbial modulations that would increase GLP-2 secretion and extend its half-life in the ileum 
in our SBS piglet model. Further research into the role of enteric leukocytes, barrier function, 
and mitochondrial metabolism requires investigation. 
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3.6 FIGURES AND TABLES 
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Figure 3.1 (cont.) Immunohistochemistry of L cells in the distal ileum (left) and proximal colon (right) of 
piglets following 80% ileojejunal resection receiving 80% parenteral nutrition and 20% enteral nutrition 
supplemented with: nothing, control (CON); 10g/L short-chain fructooligosaccharide, prebiotic (PRE); 109 
colony forming units Lactobacillus rhamnosus GG, probiotic (PRO); or PRE + PRO, synbiotic (SYN) for 7 
days. Data points represent the value for each subject within a treatment group, with the horizontal black bar 
representing the treatment mean, n = 8. P values are shown for ANOVA across treatments. There were no 
differences in L-cell density (A) between treatment groups in the ileum or colon, but a higher L density in the 
ileum vs the colon. There were also no differences in total GLP2 related fluorescence (B) or fluorescence per 
L cell (C).
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Figure 3.2 Transcription of Glucagon-like peptide 2 (GLP-2) signaling primary targets in the distal ileum 
(left) and proximal colon (right). Unsupplemented enteral nutrition, Control (CON); 10g/L short-chain 
fructooligosaccharide, prebiotic (PRE); 109 colony forming units Lactobacillus rhamnosus GG, probiotic 
(PRO); or PRE + PRO, synbiotic (SYN) for 7 days. Bars represent the mean of each treatment group ± SEM; 
CON, PRE, PRO n = 10, SYN n = 9. P values are shown for ANOVA across treatments; A,B different letters 
between treatment means represents a significant difference with LSD. FFAR2 = Free fatty acid receptor 2 
(A), FFAR3 = Free fatty acid receptor 3 (B), GCG = Proglucagon (C), DPP-IV = Dipeptidyl peptidase 4 (D), 
GLP-2R = Glucagon-like peptide 2 receptor (E). 
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Figure 3.2 (cont) Transcription of Glucagon-like peptide 2 (GLP-2) signaling downstream targets in the 
distal ileum (left) and proximal colon (right). Unsupplemented enteral nutrition, Control (CON); 10g/L short-
chain fructooligosaccharide, prebiotic (PRE); 109 colony forming units Lactobacillus rhamnosus GG, 
probiotic (PRO); or PRE + PRO, synbiotic (SYN) for 7 days. Bars represent the mean of each treatment 
group ± SEM; CON, PRE, PRO n = 10, SYN n = 9. P values are shown for ANOVA across treatments; A,B 
different letters between treatment means represents a significant difference with LSD. IGF-1 = Insulin-like 
growth factor 1 (A), IGF-1R = Insulin-like growth factor 1 receptor (B), IGF-2 = Insulin-like growth factor 2 
(C), IGF-2R = Insulin-like growth factor 2 receptor (D).
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Figure 3.5 Transcription of motility-related enteroendocrine hormones in the distal ileum (left) and proximal 
colon (right). Unsupplemented enteral nutrition, Control (CON); 10g/L short-chain fructooligosaccharide, 
prebiotic (PRE); 109 colony forming units Lactobacillus rhamnosus GG, probiotic (PRO); or PRE + PRO, 
synbiotic (SYN) for 7 days. Bars represent the mean of each treatment group ± SEM; CON, PRE, PRO n = 
10, SYN n = 9. P values are shown for ANOVA across treatments; A,B different letters between treatment 
means represents significant difference with LSD. PYY = Peptide tyrosine-tyrosine (A); CCK = 
Cholecystokinin (B).
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Figure 3.6 Transcription of nitric oxide-producing genes in the distal ileum (left) and proximal colon (right). 
Unsupplemented enteral nutrition, Control (CON); 10g/L short-chain fructooligosaccharide, prebiotic (PRE); 
109 colony forming units Lactobacillus rhamnosus GG, probiotic (PRO); or PRE + PRO, synbiotic (SYN) 
for 7 days. Bars represent the mean of each treatment group ± SEM; CON, PRE, PRO n = 10, SYN n = 9. P 
values are shown for ANOVA across treatments; A,B different letters between treatment means represents a 
significant difference with LSD. eNOS = endothelial nitric oxide synthase (A), iNOS = inducible nitric oxide 
synthase (B).
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Figure 3.7 Transcription inflammatory markers in the distal ileum (left) and proximal colon (right). 
Unsupplemented enteral nutrition, control (CON); 10g/L short-chain fructooligosaccharide, prebiotic (PRE); 
109 colony forming units Lactobacillus rhamnosus GG, probiotic (PRO); or PRE + PRO, synbiotic (SYN) 
for 7 days. Bars represent the mean of each treatment group ± SEM; CON, PRE, PRO n = 10, SYN n = 9. P 
values are shown for ANOVA across treatments; A,B different letters between treatment means represents a 
significant difference with LSD. IFNg = Interferon gamma (A), IL1B = Interleukin 1 beta (B), IL6 = 
Interleukin 6 (C), TNFa = Tumor necrosis factor alpha (D).
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Figure 3.9 Ileal FFAR2 expression is correlated to TNFa, but not L-cell density. Pearson correlation between 
gene expression of FFAR2 and TNFa (A) displayed a moderate relationship, but Pearson correlation between 
FFAR2 and L-cell density (B) showed no significant relationship.
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CHAPTER 4: MECHANISMS UNDERLYING INTESTINAL 
ADAPTATION EXPLAINED BY BIOINFORMATICS APPROACHES 
IN A NEONATAL PIGLET MODEL OF SHORT-BOWEL 
SYNDROME TREATED WITH PRE-, PRO-, AND SYNBIOTIC 
 
4.1 ABSTRACT 
 Understanding the complex physiological interactions which facilitate structural and 
functional intestinal adaption in patients with short-bowel syndrome (SBS) requires an approach 
that encompasses all intestinal functions, due to the heterogeneous nature of remnant intestine in 
this patient population. Each of prebiotic, probiotic, and synbiotic interventions created varied 
responses in our neonatal piglet model of SBS, further necessitating the need to understand 
personal responses to treatment. However, the volume of data needed to capture all such 
functions and responses poses a problem to standard data analysis methods. Therefore, we aimed 
to identify key traits that differentiated our four treatment groups utilizing linear discriminant 
analysis (LDA), and to develop statistical models that could explain changes in specific 
structural and functional adaptations using multiple linear regression (MLR). Three MLR models 
were generated to predict ileal villus height (R2 adjusted = 0.890, 0.793, and 0.753; all P < 0.001) 
two MLP were generated to predict colonic electrogenic glutamine transport (R2 adjusted = 
0.815 and 0.655; both P < 0.001), and one LDA was conducted to differentiate between 
treatment groups in each the ileum and the colon (all groups completely differentiated with 100% 
confidence and P < 0.0001). While factors related to microbial and enteroendocrine activity were 
prominent in the models and reflected many of our previous hypotheses, relationships between 
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variables related to inflammation, barrier function, and membrane transporters require further 
investigation. 
 
4.2 BACKGROUND 
 The process of intestinal adaptation following massive small bowel resection and short-
bowel syndrome (SBS) is a complex biological process that encompasses innate, acute responses 
that occur almost immediately following surgery as well as environmentally influenced, chronic 
adaptation which is believed to continue for years following surgery. Structural adaptations 
occur through hyperplasia of the remnant tissue, requiring signaling from trophic hormones and 
restructuring of cellular junctions, while functional adaptations require enhanced expression of 
pathways related to nutrient processing, motility, immunity, and barrier function. Understanding 
the mechanisms behind these processes and their response to environmental stimuli, such as 
therapies that leverage the intestinal microbiota, requires an approach that encompasses all such 
forces at play. 
 However, the volume of data needed to even marginally describe all such processes poses 
a problem to standard methods of data analysis. Such high-dimensional data sets, especially 
those including DNA sequencing and high-throughput gene expression assays, result in 
thousands more variables than there are subjects. Approaching these data sets requires a strategy 
which first reduces the dimensionality of the variables (either through identifying key variables 
or creating pseudo-variables which replace many covariates) before proceeding to proper 
analysis. 
 We have previously reported robust structural and functional adaptations in a preclinical, 
neonatal piglet model of short-bowel syndrome treated with prebiotic short-chain 
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fructoologisaccharide (scFOS), but to a lesser extent when treated with probiotic Lactobacillus 
rhamnosus GG (LGG) and synbiotic combination of the two. These changes are associated with 
modifications to the intestinal microbiota and enteroendocrine system, but the extent to which 
each of these changes facilitated intestinal adaptation in our model remains uncertain. The SBS 
patient population is heterogeneous in terms of remaining intestinal mass, architecture, and 
function, which greatly impacts their response to various treatments (Lim et al., 2017). 
Understanding intestinal function as a whole -from a systems biology approach- rather than from 
the perspective of a single enzyme, hormone, or histological marker will help improve 
personalized patient care. Therefore, the purpose of this study was to identify key traits that 
differentiated our four treatment groups (utilizing linear discriminant analysis), and to develop 
statistical models that could explain changes in specific structural and functional adaptations 
(using multiple linear regression) in a data set including physiological, histological, microbial 
DNA sequencing, and high throughput gene expression data. 
 
4.3 METHODS 
4.3.1 Animals, treatment groups, and data 
Our neonatal piglet model of SBS and treatment groups were previously described (see chapter 
2). As a reminder, all piglets received 80% jejunoileal resection; to meet their nutrient 
requirements, control group (CON) received 80% parenteral nutrition and 20% enteral nutrition 
(EN), prebiotic group (PRE) received CON + 10g/L scFOS supplemented in EN, probiotic group 
received CON + 109 colony forming units of LGG supplemented in EN, and synbiotic group 
(SYN) received CON + scFOS + LGG. 
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 The variables utilized for all analyses are listed in Table 4.1. Collection of this data was 
described in chapters 2 and 3, and (Barnes et al., 2012). All analyses were conducted in JMP Pro 
12.2.0. Subjects were excluded from model building only when they were missing a data point 
for a variable that became included in the given model. 
 
4.3.2 Multiple linear regression with purposeful selection of variables 
To narrow down the number of variables for multiple regression analysis, a purposeful selection 
approach was taken (Bursac et al., 2008; Zhang, 2016). While not an assumption of multiple 
regression, data that was not normally distributed was transformed to fit a normal distribution to 
reduce the impact of potential outliers on the model and meet the assumptions of univariate 
analysis. A univariate analysis was conducted for each variable with a cutoff p-value of 0.25 for 
initial inclusion in each model. Concurrently, the assumption of equal regression amongst 
treatments was tested to meet the assumptions of multiple linear regression with a conservative 
cutoff of ≤ 0.15 for exclusion, given the small sample size. Variables not meeting the assumption 
of equal regression were used to create a second model in the same fashion as the first, which 
also controlled for treatment.  
Variables that met both requirements of the univariate test and equal regression were 
included in the initial statistical model. At this point, variables were removed in a backwards 
fashion, eliminating the variable with the largest p-value one at a time. An exception was made 
when the removal of a variable decreased the R2 adjusted by ≥ 0.1; these variables remained in 
the model due to their potential interactions with other variables. Elimination of variables 
continued until all variables in the model were significant (P ≤ 0.05) or were given the previous 
exception. At this point, variables remaining in the model that had biological relevance to one 
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another (ex: two proteins which are known to interact physically) were tested for significant 
interactions. The p-value cutoff for the final model was set at ≤ 0.01, R2 adjusted is reported. 
Final residuals of the model were tested and met the assumption of normality. 
An attempt was made to build a third model utilizing variables that were initially 
included, but subsequently removed from the first model. The same procedure to construct the 
first model was utilized. 
 
4.3.3 Linear Discriminate Analysis 
To determine which variables best differentiated between our treatment groups, we conducted 
linear discriminate analyses. Due to the large number of variables, each was selected for 
inclusion in a forward fashion, meaning that the variable with the lowest p value (and thus 
highest contribution to discriminating between the treatment groups) was added one at a time 
until the next variable to be selected was no longer significant to the model (P > 0.05). At this 
point the model was generated utilizing the included variables. If all subjects were categorized 
into their treatment group with 100% accuracy and certainty, the analysis ended. If any 
uncertainty remained, the next most significant variable (even if P > 0.05) was added into the 
model until 100% certainty was reached for all subjects. 
 
4.4 RESULTS 
4.4.1 Enteroendocrine signaling, microbial interactions, and barrier formation explain changes 
in ileal villus height 
Three multiple linear models were generated to explain the structural adaptation of increased 
ileal villus length. Ileal villus length was chosen as the representative structural adaptation due to 
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the drastic differences between our treatment groups and physiological importance to nutrient 
processing. The first model encompasses factors related to enteroendocrine function, perfusion, 
and short-chain fatty acid (SCFA) handling; N = 25, R2 adjusted = 0.890, P < 0.0001, root mean 
square error (RMSE) = 49.9, mean villus length = 465 μm (Figure 4.1). The top three 
contributing factors from highest to lowest were: expression of Dipeptidyl peptidase IV (DPP-
IV) mRNA, expression of endothelial nitric oxide synthase (eNOS) mRNA, and expression of 
Insulin-like growth factor binding protein 4 (IGFBP4) mRNA. 
 The second model encompasses 9 factors related to the interactions between abundance 
of butyrate-producing bacteria, Lactobacillus spp. that produce solely D-lactate, and Bacteroides 
spp. when controlling for treatment; N = 27, R2 adjusted = 0.793, P < 0.01, RMSE = 68.5, mean 
villus length = 462.5 μm (Figure 4.2). The top three contributing factors from highest to lowest 
were: interaction between Treatment*Total Butyrate-producers (TBP), interaction between 
TBP*D-Lactate producing Lactobacillus, and Treatment. 
 The third model encompasses 13 factors related to barrier function, inflammation, and 
tissue remodeling; N = 27, R2 adjusted = 0.753, P < 0.001, RMSE = 74.7, mean villus length = 
462.5 μm (Figure 4.2). The top three contributing factors from highest to lowest were: 
expression of claudin-1 (CLDN-1) mRNA, expression of occludin (OCLN) mRNA, and 
expression of ST6 Beta-Galactoside Alpha-2,6-sialyltransferase 1 (ST6GAL1) mRNA. 
 
4.4.2 Interactions between growth, glucagon-like peptide 2 signaling, and inflammation drive 
changes in colonic glutamine absorption 
Two multiple linear models were developed to explain the functional adaptation of increased 
electrogenic glutamine transport in the colon. Colonic glutamine transport was chosen as the 
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representative functional adaptation since glutamine is the second most preferred energy 
substrate of colonocytes (after butyrate). The first model encompasses 9 factors related to 
glutamine sensing, barrier function, and energy utilization for growth; N = 20, R2 adjusted = 
0.815, P < 0.001, RMSE = 0.953, mean electrogenic glutamine transport (area under the curve) = 
3.17 (Figure 4.3). The top three contributing factors from highest to lowest were: expression of 
OCLN mRNA, expression of inducible nitric oxide synthase (iNOS) mRNA, and interaction 
between expression of claudin-4*matrix metalloproteinase 9 (CLDN4*MMP9) mRNA. 
 The second model encompasses 15 factors related to growth, SCFA handling, and 
glutamine transporters; N = 35, R2 adjusted = 0.656, P < 0.001, RMSE = 1.77, mean electrogenic 
glutamine transport (area under the curve) = 4.18 (Figure 4.4). The top three contributing factors 
from highest to lowest were: expression of monocarboxylate transporter 1 (MCT1) mRNA, 
expression of Large neutral amino acid transporter 1 (LAT1) mRNA, and interaction Insulin-like 
growth factor 2 receptor (IGF-2R)*IGFBP4. 
 
4.4.3 Results of Linear Discriminant Analysis 
Three canonicals (axes C1-C3) were generated for the ileum (Figure 4.5) and colon (Figure 4.6) 
for discrimination between treatment groups. For the ileum, 13 variables were included in the 
final model in the following order: villus height, abundance of D-lactate producing 
Lactobacillus, SMCT1, DPP-IV, proliferation, GLP-2R, MMP4, GAL3ST3, OCLN, PYY, 
CLDN3, CCH, and SLC9A2. CON was differentiated from other treatment groups equally along 
C1 and C2, while other treatment groups were primarily differentiated from each other along C1. 
All four treatment groups clustered distinctly from one another, demonstrated by comparison of 
within group distances to between group distances (all P < 0.0001). 
	 98 
 For the colon, 10 variables were included in the final model in the following order: 
IGFBP3, CLDN5, SGLT1, ST6GAL1, SLC27A4, IL6, abundance of total Lactobacillus, circular 
muscularis height, final plasma GLP-2, and TNFa. All groups were primarily differentiated by 
C1, except for PRO vs SYN. PRO and SYN were differentiated by C2, which also served to 
differentiate between CON and PRE about half as much as C1. All four treatment groups 
clustered distinctly from one another, demonstrated by comparison of within group distances to 
between group distances (all P < 0.0001). 
 
4.5 DISCUSSION 
 Our goal was to discriminate between treatment groups and propose mechanisms 
underlying key changes in intestinal adaptation. The structural adaptation of ileal villus length 
was very well explained by the primary model (R2 adjusted = 0.890), and the functional 
adaptation of colonic electrogenic glutamine transport was also reasonably well explained (R2 
adjusted = 0.815). Measuring more factors related to transporter abundance, post-translational 
modifications, and serum markers may enhance the predictive power of these models. 
 The first model for villus height had a significant number of factors related to 
enteroendocrine function, strengthening our assertion that enhanced intestinal adaptation 
associated with the scFOS containing treatments were driven by enteroendocrine modulation 
(see chapter 3). Again, reduced local expression of DPP-IV stands out an important aspect of 
these physiological changes. Furthermore, the inclusion of eNOS potentially reaffirms the role of 
these factors in GLP-2 enhanced perfusion (Guan et al., 2003), Digesters of scFOS, bacterial 
syntrophy, and the relative abundance fermentation products (especially butyrate and lactate) can 
drive changes in the intestinal epithelium (see chapter 2). Interestingly, the isomer of lactate 
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produced may carry higher physiological relevance, as abundance of solely D-lactate producing 
Lactobacillus spp. remained in the model while total Lactobacillus was removed. This aligns 
well with the vulnerability to D-lactic acidosis exhibited by infants with SBS. 
 The final model of ileal villus length addresses the changes in barrier function that would 
be necessary in the remodeling of longer villi. These aspects seem to be driven by changes in 
expression of different tight junction proteins and functional inflammation. In this scenario, 
immune cells may be recruited to the area to direct restructuring of cell-to-cell adhesions, as 
MMP9 and MMP14 are induced by IL-6, IL-10, and TNFa (Cathcart et al., 2016; Kothari et al., 
2014). 
Switching gears, the first model for colonic electrogenic glutamine transport reflects 
variables upregulated in growing tissue, modulating perfusion in response to bacterial invasion 
(iNOS), and tight junction remodeling (OCLN, CLDN4, MMP9). Furthermore, the sensing of 
luminal glutamine may serve to regulate its uptake, as TAS1R1 and TAS1R3 form taste receptor 
heterodimer which is most highly stimulated by glutamine, which are found in the membrane of 
enteroendocrine L-cells (Tolhurst et al., 2011). 
Finally, the second model for colonic electrogenic glutamine transport also reflects 
enteroendocrine involvement in functional adaptation. Notably, both apical transporter of 
glutamine ATB0+ and basolateral amino acids transporters LAT1 and LAT2 contribute to this 
model, indicating that enhanced glutamine absorption could also be related to amino acid export 
from the colon. 
We successfully identified key variables that distinguish all four of our treatment group 
through linear discriminant analysis. In the ileum, again enteroendocrine modulation helped 
distinguish between our groups, notably DPP-IV, as well as markers of structural adaptation such 
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as villus height and proliferation. In the colon, a wide range of variables contributed to 
differentiation between the treatment groups. How these disparate factors may interact 
physiologically requires further study. 
Overall, the variables identified in this study can serve as a stepping-stone to developing 
more effective treatments for SBS, including development of an optimal synbiotic treatment as 
well as identification of biological pathways which can be targeted to enhance ileal surface area 
and glutamine absorption. 
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4.6 FIGURES AND TABLES 
  
Figure 4.1 Multiple linear regression modeling of ileal villus height; Model 1. Acronyms for each variable 
are explained in Table 4.1. Variables were chosen by purposeful selection (based on univariate model 
significance) and then removed in a backwards fashion until only significant variables remained (either P ≤ 
0.05 or removal resulting in decreased R2 adjusted ≥ 0.1). Significance of each variable to the model (A), fit 
of the overall model (B), residuals (C), and final predictive equation (D) are shown.
(A) Effect Summary 
(D) Linear Equation 
(B) Fit Statistics 
   R2 adjusted = 0.890 
   RMSE = 49.9 
   Mean Villus Ht = 465 
   N = 25 
   P < 0.001	
Villus height = -636(DPP-IV) – 342(log[eNOS]) – 137(1 ÷ IGFBP4) + 437(GCG) - 
169(IGFBP3) - 267(log[IGFBP2]) - 208(log[SMCT1]) - 4.82(L-cell_Density) + 
144(log[MCT1]) - 0.834(Final_Plasma_GLP2) + 162(log[FFAR2]) - 6.5(log[IFNg]) 
(C) Actual vs Predicted 
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Figure 4.2 Multiple linear regression modeling of ileal villus height; Model 2. Acronyms for each variable 
are explained in Table 4.1. Variables were chosen by purposeful selection (based on univariate model 
significance) and then removed in a backwards fashion until only significant variables remained (either P ≤ 
0.05 or removal resulting in decreased R2 adjusted ≥ 0.1). Treatment is included to control for unequal 
regression between groups. Significance of each variable to the model (A), fit of the overall model (B), 
residuals (C), and final predictive equation (D) are shown. TRT1 = -401 (CON), -369 (PRE), 724 (PRO), 383 
(SYN); TRT2 = -0.81 (CON), -0.84 (PRE), 3.1 (PRO), 1 (SYN); TRT3 = -0.10 (CON), -0.12 (PRE), 0.31 
(PRO), 1 (SYN); TRT4 = -0.00039 (CON), -0.00046 (PRE), 0.00098 (PRO), 1 (SYN); TRT5 = -1.1 (CON), 
-3.0 (PRE), -0.94 (PRO), 1 (SYN).
(A) Effect Summary 
(B) Fit Statistics 
   R2 adjusted = 0.793 
   RMSE = 68.5 
   Mean Villus Ht = 463 
   N = 27 
   P < 0.01	
(C) Actual vs Predicted 
(D) Linear Equation 
Villus height = TRT1 + (TRT2)*(TBP – 378)  
– 0.014(TBP – 378)*(D-Lac – 72) + 0.00033(TBP  
– 378)*(TBac – 4239) + 0.080(TBac) + (TRT3)*(TBac 
– 4239) + (TRT4)*(TBP – 378)*(TBac – 4239)  
– 2.4(D-Lac) + (TRT5)*(D-Lac – 72) 
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Figure 4.3 Multiple linear regression modeling of ileal villus height; Model 2. Acronyms for each variable 
are explained in Table 4.1. Variables were chosen by purposeful selection (based on univariate model 
significance), excluding variables included in Model 1, and then removed in a backwards fashion until only 
significant variables remained (either P ≤ 0.05 or removal resulting in decreased R2 adjusted ≥ 0.1). 
Significance of each variable to the model (A), fit of the overall model (B), residuals (C), and final predictive 
equation (D) are shown.
(A) Effect Summary 
(D) Linear Equation 
(B) Fit Statistics 
   R2 adjusted = 0.753 
   RMSE = 74.7 
   Mean Villus Ht = 463 
   N = 27 
   P < 0.001	
Villus height = -251(log[CLDN1]) – 291(OCLN) + 335(ST6GAL1) – 327(CLDN4) 
 – 36(Enterococcus faecalis) + 323(log[IGFBP2]) + 464(1÷√MMP14) + 226(√TNFa)  
+ 535(1÷√MMP14 – 1.1)*(log[IL6] + 0.14) + 96(SLC26A3) + 127(log[IL6]  
+ 0.14)*(√TNFa – 0.98) – 47(RELMβ) – 32(log[IL6]) - 35 
(C) Actual vs Predicted 
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Figure 4.4 Multiple linear regression modeling of colonic electrogenic glutamine transport; Model 1. 
Acronyms for each variable are explained in Table 4.1. Variables were chosen by purposeful selection (based 
on univariate model significance) and then removed in a backwards fashion until only significant variables 
remained (either P ≤ 0.05 or removal resulting in decreased R2 adjusted ≥ 0.1). Significance of each variable 
to the model (A), fit of the overall model (B), residuals (C), and final predictive equation (D) are shown.
(A) Effect Summary 
(D) Linear Equation 
(B) Fit Statistics 
   R2 adjusted = 0.815 
   RMSE = 0.953 
   Mean Gln = 3.17 
   N = 20 
   P < 0.001	
Electrogenic glutamine transport = 9.2(OCLN) – 4.8(log[iNOS]) + 1.7(log[IL6])  
– 5.0(log[TAS1R3]) -2.8(log[CLDN4] + 0.65)*(log[MMP9] – 0.38) – 
0.61(log[MUC4]) + 1.1(log[TAS1R1]) + 0.93(Muc_Wt) + 2.0(CPT1a) 
(C) Actual vs Predicted 
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Figure 4.5 Multiple linear regression modeling of colonic electrogenic glutamine transport; Model 1. 
Acronyms for each variable are explained in Table 4.1. Variables were chosen by purposeful selection (based 
on univariate model significance) and then removed in a backwards fashion until only significant variables 
remained (either P ≤ 0.05 or removal resulting in decreased R2 adjusted ≥ 0.1). Significance of each variable 
to the model (A), fit of the overall model (B), residuals (C), and final predictive equation (D) are shown.
(A) Effect Summary 
(D) Linear Equation 
(B) Fit Statistics 
   R2 adjusted = 0.655 
   RMSE = 0.1.77 
   Mean Gln = 4.18 
   N = 35 
   P < 0.001	
Electrogenic glutamine transport = 6.4(√MCT1) + 5.2(log[LAT1])  
+ 11(log[IGF-2R]) + 39(IGF-2R – 0.52)*(log[IGFBP2] + 0.15) – 42(IGF-2R  
– 0.52)*(log[IGFBP4] – 0.56) – 2.3(ATB0+) – 5.8(√FFAR3) + 1.8(log[LAT2]) 
– 3.9(log[GLP-2R]) – 2.1(log[DPP-IV]) +0.066(Col_Length) + 2.7(log[IGF-1])  
+ 4.5(log[IGF-1R]) + 1.9(log[IGFBP2]) – 2.8(log[IGFBP4]) – 7.0 
(C) Actual vs Predicted 
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TABLE 4.1. Variables utilized in Mulitvariate Linear Regression and Linear 
Discriminant Analysis 
Name Abbreviation 
Total_Intestinal_Length NA 
Total_Intestinal_Wt NA 
Final_Wt NA 
Segment_Length Col_Length 
Segment_Wt NA 
Villus_Height Villus_Ht 
Villus_Width NA 
Crypt_Depth NA 
Apoptosis NA 
Proliferation NA 
Mucosal_Wt Muc_Wt 
Submucosal_Wt NA 
Muscularis_Longitudinal NA 
Muscularis_Circular NA 
Muscularis_Total NA 
Transmural_Thickness NA 
Lcell_Density NA 
Total_Fluorescence NA 
Final_Plasma_GLP2 Plasma_GLP2 
Sucrase NA 
Lactase NA 
Transepithelial Resistance NA 
Electrogenic Glucose Transport NA 
Electrogenic Glutamine Transport Gln 
Electrogenic Glycine Transport  
Electrogenic Proline Transport  
Electrogenic Arginine Transport  
Electrogenic Threonine Transport  
Serotonin  
Carbachol  
Monocarboxylic Acid Transporter 1/Solute Carrier Family 16, Member 1 MCT1 
Sodium/Monocarboxylate Cotransporter/Solute Carrier Family 5, Member 8 SMCT1 
Free Fatty Acid Receptor 2 FFAR2 
Free Fatty Acid Receptor 3 FFAR3 
Glucagon GCG 
Dipeptidyl Peptidase 4 DPP-IV 
Insulin-like growth factor 1 IGF-1 
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Table 4.1 (cont.) Variables utilized in Mulitvariate 
Linear Regression and Linear Discriminant Analysis 
 
Glucagon-like peptide 2 receptor 
 
 
 
 
GLP-2R 
Insulin-like growth factor 1 receptor IGF-1R 
Mucin 1 MUC1 
Mucin 2 MUC2 
Mucin 3 MUC3 
Mucin 4 MUC4 
Mucin 5AC MUC5AC 
Mucin 13 MUC13 
Caudal Type Homeobox 2 CDX2 
Zonula Occludens Protein 1 ZO1 
Zonula Occludens Protein 2 ZO2 
Claudin 1 CLDN1 
Claudin 2 CLDN2 
Claudin 3 CLDN3 
Claudin 4 CLDN4 
Claudin 5 CLDN5 
Claudin 6 CLDN6 
Claudin 7 CLDN7 
Claudin 8 CLDN8 
Claudin 15 CLDN15 
Occludin OCLN 
 Cadherin 1 CDH1 
Matrix Metallopeptidase 1 MMP1 
Matrix Metallopeptidase 2 MMP2 
Matrix Metallopeptidase 3 MMP3 
Matrix Metallopeptidase 9 MMP9 
Matrix Metallopeptidase 12 MMP12 
Matrix Metallopeptidase 14 MMP14 
 Carbohydrate Sulfotransferase 5 & 6 CHST5/6 
Galactose-3-O-Sulfotransferase 2 GAL3ST2 
Galactose-3-O-Sulfotransferase 3 GAL3ST3 
Resistin Like Beta RELMβ 
ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1 ST6GAL1 
Trefoil Factor 3 TFF3 
Interferon Gamma IFNg 
Interleukin 1 Beta IL1B 
Interleukin 6 IL6 
Tumor Necrosis Factor Alpha TNFa 
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Table 4.1 (cont.) Variables utilized in Mulitvariate 
Linear Regression and Linear Discriminant Analysis 
 
Glucose transporter 2/Solute Carrier Family 2 Member 2 
 
 
 
 
GLUT2 
Glucose transporter 5/Solute Carrier Family 2 Member 5 GLUT5 
Sodium/Glucose Cotransporter 1/Solute Carrier Family 5 Member 1 SGLT1 
Solute Carrier Family 1 (Neutral Amino Acid Transporter), Member 5 ASCT2 
Solute Carrier Family 6 (Amino Acid Transporter), Member 14 ATB_0+ 
Solute Carrier Family 6 (Neutral Amino Acid Transporter), Member 19 B0AT1 
Excitatory Amino Acid Transporter 2/Glutamate/Aspartate Transporter II EAAT2 
Excitatory Amino Acid Transporter 3/Sodium-Dependent Glutamate/Aspartate 
Transporter 3 EAAT3 
Large Neutral Amino Acids Transporter Small Subunit 1 LAT1 
Large Neutral Amino Acids Transporter Small Subunit 2 LAT2 
Peptide Transporter 1 PEPT1 
Neutral and Basic Amino Acid Transport Protein RBAT  rBAT 
Sodium-Coupled Neutral Amino Acid Transporter 2 SNAT2 
Cluster Determinant 36 CD36 
 Retinol Binding Protein 2 RBP2 
Fatty Acid Transporter/Solute Carrier Family 27, Member 4 SLC27A4 
AMP-Activated Protein Kinase AMPK 
Carnitine Palmitoyltransferase 1A CPT1a 
Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha PGC1a 
Nitric Oxide Synthase 3 (Endothelial Cell) eNOS 
Nitric Oxide Synthase 2A (Inducible) iNOS 
Cholecystokinin CCK 
Insulin-like growth factor 2 IGF-2 
Insulin-like growth factor 2 Receptor IGF-2R 
Insulin Like Growth Factor Binding Protein 2 IGFBP2 
Insulin Like Growth Factor Binding Protein 3 IGFBP3 
Insulin Like Growth Factor Binding Protein 4 IGFBP4 
Peptide Tyrosine Tyrosine PYY 
 Taste 1 Receptor Member 1 TAS1R1 
 Taste 1 Receptor Member 2 TAS1R2 
 Taste 1 Receptor Member 3 TAS1R3 
 Taste 2 Receptor Member 38 TAS2R38 
ATPase Na+/K+ Transporting Subunit Alpha 1 ATP1A1 
 Chloride Anion Exchanger/Solute Carrier Family 26 Member 3 SLC26A3 
Sodium/Hydrogen Exchanger/Solute Carrier Family 9, Isoform 1  SLC9A1 
Sodium/Hydrogen Exchanger/Solute Carrier Family 9, Isoform 2 SLC9A2 
Sodium/Hydrogen Exchanger/Solute Carrier Family 9, Isoform 3 SLC9A3 
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Table 4.1 (cont.) Variables utilized in Mulitvariate 
Linear Regression and Linear Discriminant Analysis 
 
 
Carbonic Anhydrase 1 
 
 
 
 
 
CA1 
Carbonic Anhydrase 2 CA4 
Butyryl-CoA:Acetate CoA Transferase BCoAT 
Acetyl-CoA Synthase BFFase 
Beta-Fructofuranosidase TBP 
Total Butyrate-Producers (Ileal Digesta)  
Total Lactobacillus (Ileal Digesta) TLB 
Total D-Lactate Producing Lactobacillus (Ileal Digesta) D-Lac 
Total_Bacteroides(Ileal Digesta) TBac 
Escherichia_coli_E851/71(Ileal Digesta) NA 
Enterococcus_faecalis(Ileal Digesta) NA 
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CHAPTER 5: FUTURE DIRECTIONS 
 
 
One of the overarching themes of this research has been the unpredictable differences 
between the prebiotic treatment (PRE) [short-chain fructooligosacchraide (scFOS)] which 
robustly stimulated intestinal adaptation in the neonatal piglet model of short-bowel syndrome 
(SBS), and the synbiotic treatment (SYN) [scFOS plus Lactobacillus rhamnosus GG (LGG)] 
which in many ways was unique from either scFOS or LGG alone. If SYN had been at least as 
successful as PRE, then perhaps development of a synbiotic therapy would not be warranted. 
However, the apparent blunting of many intestinal adaptations in SYN compared to PRE points 
out a very important gap in knowledge. Future research should strive to create a synbiotic 
combination by finding a probiotic that works well with the already successful prebiotic scFOS. 
Moving forward, developers should bear in mind several aspects of this research, including how 
(if at all) the probiotic will digest the prebiotic, how the microbial community will be impacted 
by the process of prebiotic fermentation, and how the major products of this microbial syntrophy 
will impact the host’s intestinal epithelium. Specifically, a probiotic species that externally 
digests scFOS such as a Bifidobacterium or Bacteroides species could be beneficial, if not a 
butyrate-producing bacteria able to digest scFOS itself. However, FDA approval of the latter two 
options could pose a barrier, especially in such a vulnerable population as infants with SBS. 
 Another major theme emerging from this research is the importance played by the down-
regulation of dipeptidyl-peptidase-IV (DPP-IV) expression. While DPP-IV inhibitors are 
currently being developed, perhaps insight into the mechanism of how both the PRE and 
probiotic (PRO) treatments, yet not SYN, was able to reduce DPP-IV mRNA levels could be 
very useful. This may be especially important if side effects are discovered during this 
development process, since glucagon-like peptide 2 (GLP-2) is not the only hormone or protein 
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whose activity is regulated by DPP-IV. If scFOS is just as effective at reducing DPP-IV, then it 
could represent a cost-effective therapy without the need for a potentially expensive DPP-IV 
targeting medication. 
 Finally, the role of other cells types in this process of intestinal adaptation should be 
explored. Goblet cells (for their ability to regulate barrier function and enterocyte 
differentiation), submucosal leukocytes (for their responsiveness to short-chain fatty acids and 
potential role in epithelial remodeling), and myofibroblasts (for their regulation of 
enteroendocrine responses) were a few targets implicated by this research, but were not actively 
pursued. Enhancing coordination between these cell types, enteroendocrine cells, and enterocytes 
could maximize intestinal adaptation in response to future synbiotic treatments.  
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